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Community-associated methicillin-resistant S. aureus (CA-MRSA)
infections are the leading cause of community bacterial infections in the United
States. Genes encoding Panton-Valentine leukocidin (PVL) are present in most
Staphylococcus aureus strains that cause CA-MRSA infections. Despite an
association of PVL with the most abundant CA-MRSA strains, its role in
pathogenesis—if any—remains unknown. PVL is a pore-forming toxin with
specificity for myeloid cells, including polymorphonuclear leukocytes (PMNs or
neutrophils). It is widely assumed that PVL-mediated pore formation in the
plasma membrane of PMNs leads ultimately to cytolysis. However, this
hypothesis has not been tested and previous studies indicate that levels of PVL
in vivo are likely insufficient to cause host cell lysis. On the other hand, sublytic
concentrations of PVL prime neutrophils for enhanced production of reactive
oxygen species (ROS), and cause secretion of proinflammatory molecules and
granule exocytosis. The molecular basis of PVL-mediated priming is unknown.
To better understand the role played by PVL during S. aureus infection, we used
human PMNs to investigate the correlation between PVL-mediated pore
formation and cytolysis, and the molecular basis of PVL-mediated priming. Using
S. aureus culture conditions that favor high production of PVL, there was on
average more neutrophil plasma membrane permeability and cell lysis caused by
supernatants derived from wild-type (PVL-positive) CA-MRSA strains compared
to those from isogenic lukS/F-PV negative (PVL-negative) strains. Unexpectedly,
there was not always a correlation between pore formation and cell lysis caused
by S. aureus culture supernatants, and these findings were confirmed using
purified PVL. Consistent with published studies, sublytic concentrations of PVL
primed neutrophils for enhanced release of superoxide, caused upregulation of
CD11b, and accelerated apoptosis. Microarray analysis revealed changes in the
PMN transcriptome following exposure to PVL, including upregulation of
molecules involved in the proinflammatory response. Consistent with microarray
data, multiple proinflammatory molecules were released from neutrophils after
stimulation with PVL. We propose that the primary function of PVL is distinct from
leukocyte lysis—namely, that it elicits a proinflammatory response that can
enhance the host innate immune response to S. aureus infection.
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CHAPTER ONE
INTRODUCTION

1.1 Methicillin-resistant Staphylococcus aureus

1.1.1 Staphylococcus aureus (S. aureus) and the emergence of methicillinresistance
S. aureus is a Gram-positive bacterium that has a long history of causing
a wide range of infections in the human host. The pathogen is among the leading
causes of mortality by single infectious agents in the U.S. (1,2). S. aureus is also
notorious for its ability to acquire resistance to antibiotics. For example, penicillin
was introduced to treat human infections in the early 1940s and penicillinresistant strains (PRSA) emerged soon thereafter (by 1942) (3). The molecule
responsible for penicillin-resistance was identified as penicillinase (betalactamase), a plasmid-encoded enzyme that binds and hydrolyzes the betalactam ring of penicillin, rendering the antibiotic ineffective for treatment of
infection (4). Strains expressing penicillinase were frequently isolated from
patients without prior penicillin treatment, indicating in-hospital transmission of
resistant strains (5). As such, the prevalence of penicillin-resistance in
Staphylococcus increased dramatically within nosocomial settings (6). A
penicillin-resistant Staphylococcus aureus strain known as phage-type 80/81
became prominent in Australia in hospitals and the community in the 1950s and
1960s (7). Phage-type 80/81 strains ultimately became epidemic worldwide (8,9).
1

By the mid-1950s, phage-type 80 strains were the cause of 42 percent of all
outbreaks (9).
Methicillin was introduced in 1959 to treat S. aureus infections, largely
because of the increased incidence of PRSA (10). Emergence of methicillinresistant S. aureus (MRSA) occurred rapidly and initial reports of methicillinresistant strains were published in 1961; however, outbreaks remained sporadic
until the late 1960s. Industrialized countries reported increasing numbers of
nosocomial MRSA infections in the later part of the decade (11-14) and there
were warnings that MRSA would become problematic for hospitals worldwide
(15-22). In 1975, 2.4 percent of S. aureus strains isolated from US hospitals were
methicillin-resistant. By comparison, 29 percent of S. aureus isolates in 1991
were MRSA (23).
Methicillin-resistance is conferred by the mecA gene, which is encoded on
a mobile genetic element known as the Staphylococcal chromosome cassette
mec (SCCmec) (24). The mecA gene encodes a low-affinity penicillin-binding
protein, PBP2a, that enables bacterial cell wall synthesis to continue in the
presence of beta-lactam antibiotics (25). Currently, eight different SCCmec types
have been identified (I-VIII). SCCmec types I-III, and VIII encode for resistance to
multiple antibiotics, including methicillin-resistance (mecA), while types IV-VII
encode methicillin-resistance only (26).
In contrast to the PRSA pandemic, MRSA outbreaks remained largely
within the hospital setting for 30 years and MRSA is now endemic in hospitals
throughout the developed world (27-29). Immune compromised patients or
2

individuals with a predisposing risk factor, such as surgery, are particularly
susceptible to infection. In addition, transmission and spread of MRSA is
promoted in the healthcare setting by hospital staff colonized with MRSA (29,30).
Nasal carriage of MRSA (endogenous reservoirs) was reported as a risk factor
for bacteremia and infection of surgical sites (31-34). MRSA infections in which
disease onset originated from a healthcare institution is known as hospitalassociated MRSA (HA-MRSA). The use of antibiotics in healthcare settings has

Figure 1. Timeline depicting the emergence of penicillin and methicillinresistant S. aureus strains from 1940 to 2010. Green boxes represent
introduction of an antibiotic and emergence of antibiotic-resistant strains.
Blue boxes represent dissemination of resistant strains.

selected for HA-MRSA strains that are resistant to several antimicrobial agents.
As such, HA-MRSA strains typically harbor the larger SCCmec types that encode
resistance to multiple antibiotics (26). The rapid emergence of strains that are
resistant to multiple antibiotics underscores the need to develop new
therapeutics for treatment of MRSA infections (11,30,35) (Fig. 1).

1.1.2 Community-associated methicillin-resistant S. aureus (CA-MRSA)

3

The epidemiology of MRSA infections changed in the early 1990s.
Although MRSA continued to be a prominent cause of hospital-associated
infections, there were reports of MRSA outbreaks involving individuals outside of
the healthcare setting. In 1993, Udo et al. reported CA-MRSA infections in
individuals from the remote Kimberley region of Western Australia (Fig. 1) (36).
The Centers for Disease Control and Prevention (CDC) and Herold et al.
subsequently reported severe infections in pediatric patients in the Midwestern
U.S. and these individuals also had no prior hospital exposure (37,38). These
articles were among the first to report bona fide CA-MRSA infections. The
prevalence of pediatric cases treated for MRSA contracted in communities rose
from 10/100,000 admissions in 1988-1990 to 259/100,000 admissions in 1993 to
1995 (37).
CA-MRSA infections became widespread after 2003 (39) and ultimately
became epidemic in the U.S. (1,29). For example, MRSA was the causative
agent of 59 percent of all US community-associated bacterial infections in 2004
(29). These community-associated MRSA (CA-MRSA) infections often occurred
in healthy, young populations such as athletic teams, preschool children, and
military personnel (2,40,41). Skin and soft tissue infections compromise about 90
percent of all CA-MRSA infections (41). Severe CA-MRSA disease, such as
osteomyelitis, sepsis, or necrotizing pneumonia, is infrequent but these
syndromes can cause death (38,42,43-45). The ability of CA-MRSA strains to
cause infection in otherwise healthy individuals suggests that these strains have
increased virulence compared to strains that typically cause hospital infections.
4

CA-MRSA outbreaks typically occur in close-quarter environments. Direct
contact between hosts is considered to be the primary mode of transmission
(46). Contaminated fomites, such as towels and whirlpools, shared by multiple
individuals may also contribute to spread of CA-MRSA (42,47). The CDC has
developed the “Five C’s” or a list of five factors that are associated with risk of
infection: 1) crowded environments; 2) frequent skin-to-skin contact with an
infected or colonized person; 3) compromised skin (skin injuries); 4)
contaminated items or surfaces; 5) lack of cleanliness or personal hygiene
(http://www.cdc.gov/niosh/topics/mrsa/). In addition, the CDC provides specific
guidelines to prevent further spread of CA-MRSA infections as follows: 1) keep
the infected area covered with a clean, dry bandage; 2) wash hands with soap
and water or use an alcohol-based hand gel, particularly after touching the
infected area 3) maintain good personal hygiene 4) avoid sharing items that were
exposed to the affected area with other individuals; 5) consistently launder
clothing that has come in contact with the infected area; 6) limit activities
involving skin-to-skin contact if infected area cannot be covered with a clean, dry
bandage; 7) clean shared surfaces or equipment with detergent/disinfectant that
specifies S. aureus on the product label (http://www.cdc.gov/ncidod/dhqp/pdf/ar/
CAMRSA _ExpMtgStrategies.pdf). Application of the topical antibiotic mupirocin
was recommended by Raz et al. to control recurrent CA-MRSA outbreaks (48).
Notwithstanding, a study completed within the military population suggested such
treatment does not decrease CA-MRSA colonization rates (49).

5

One method to categorize or type strains is based on pulsed-field gel
electrophoresis (PFGE). PFGE banding patterns of S. aureus strains with the
same or similar patterns belong to the same PFGE type (11,45). Comparison of
PFGE banding patterns from different isolates provides information about the
relatedness of the isolates and is appropriate for understanding the molecular
epidemiology of outbreaks. Isolates from community-associated infections are
genetically distinct from those that cause hospital-associated infections,
suggesting there has been de novo emergence of the most prominent CA-MRSA
strains rather than emergence from existing prominent HA-MRSA strains (50).
The predominant HA-MRSA strains in the U.S. are PFGE types USA100,
USA200, USA500, USA600, and USA800 (52). To date, the CA-MRSA epidemic
in the U.S. consists of two predominant PFGE types, USA400 and USA300
(29,30,38,40-42). In addition to PFGE, multi-locus sequence typing (MLST or ST)
can be used to determine the molecular epidemiology of MRSA infections. The
ST of each strain is determined by single nucleotide polymorphisms (SNPs)
present in seven housekeeping genes. Strains that have identical sequences at
all seven loci are assigned to the same ST (11,51).
USA400 outbreaks occurred in the late 1990s; however, the occurrence of
USA400 infections has diminished in the US and USA300 has become the main
cause of CA-MRSA infections (Fig. 1) (29,52). The molecular basis for the
success of USA400 and USA300 as human pathogens remains unclear. Whole
genome sequencing and analysis of MW2, the prototype USA400 strain (53), and
FPR3757, a USA300 strain representative of the epidemic USA300 clone (54),
6

revealed novel genetic elements that could enhance dissemination and/or
pathogenicity. One of the notable findings was the presence of a prophage
(phiSA2mw in MW2 and phiSA2usa in FPR3757) containing genes encoding
Panton-Valentine leukocidin (PVL). The PVL genes (lukS-PV and lukF-PV) are
present in 2-5 percent of S. aureus isolates worldwide (2,55,56). Despite the
overall low percentage of S. aureus strains that harbor genes encoding PVL, the
most prominent causes of CA-MRSA infections in the U.S. and Canada are PVLpositive strains. PVL is an exotoxin that forms pores in the plasma membrane of
neutrophils, monocytes, and macrophages, host cells critical for host defense
against S. aureus. Therefore, the emergence and success of CA-MRSA as a
human pathogen was initially attributed to the presence of PVL in these strains
(56-59).

1.1.3 S. aureus evasion of human innate immunity
In general, the ability of bacteria to cause disease is linked to evasion of
the innate immune response. Polymorphonuclear leukocytes (PMNs or
neutrophils) are the most abundant cells of the innate immune system and are
essential for host defense against invading microbes (60). The importance of
these leukocytes in the control and clearance of S. aureus infections is
exemplified by patients with primary neutrophil defects. Deficiencies in
phagocytic function, especially in neutrophils, result in recurrent and possibly
fatal bacterial infections in these individuals (61). S. aureus is one of the leading
causes of infection in patients with primary neutrophil defects.
7

Release of cytokines and chemokines from the tissue or cells surrounding
the site of infection elicits an inflammatory response that includes rapid
recruitment of PMNs in vivo. Molecules secreted by bacteria or components of
the bacterial cell wall may also induce neutrophil chemotaxis and recruitment
(62,63). Exposure of neutrophils to cytokines, chemokines, or bacterial
components such as lipopolysacharride (LPS) in vitro primes these phagocytes
for enhanced production of reactive oxygen species (ROS) and granule
exocytosis following a secondary stimulus (Fig. 2) (64). N-formyl-methionyl-

Figure 2. Neutrophil
degranulation and release of
ROS after phagocytosis. A)
Phagocytosis is facilitated by
host serum proteins (antibodies
and/or complement) that bind to
the microbial surface. Following
phagocytosis, granules fuse
with the phagosomal
membrane and release
antimicrobial proteins into the
phagosome. Superoxide (O2-)
is also released into the
phagosome following
phagocytosis of microbes. B) A
transmission electron
micrograph of a human
neutrophil that has
phagocytosed S. aureus
(microbe). Reprinted with
permission from Wiley
Interdiscip. Rev. Syst. Biol.
Med. (64).
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leucyl-phenylalanine (fMLP), a representative of bacterial N-formyl peptides, is
often utilized as the secondary stimulus in in vitro assays. PMN priming also
upregulates expression of surface receptors such as CR3 (CD11b/CD18),
molecules involved in cell adhesion, phagocytosis, and activation (65-68).
At the site of infection, PMNs rapidly engulf bacteria (a process known as
phagocytosis), which are then sequestered within forming phagosomes (Fig. 2).
The process of phagocytosis is facilitated by host serum proteins (such as
antibody and complement) that opsonize microorganisms. Cytoplasmic granules
fuse with the phagosomal membrane and antimicrobial proteins such as alphadefensins are enriched in the phagosome. Concurrently, phagocytosis activates
a membrane bound NADPH oxidase to produce superoxide, which is then
converted to numerous secondary ROS within the phagosome (69-71). These
secondarily-derived ROS include hypochlorous acid, a primary constituent of
household bleach (60,70) Exposure of the pathogen to such harsh, intracellular
conditions enables PMNs to kill the ingested microbes while preventing nonspecific damage to host tissues.
Neutrophils are widely known to be associated with inflammatory diseases
such as rheumatoid arthritis, and can cause significant destruction of host tissues
should they undergo necrosis (72,73). Consequently, removal of effete
neutrophils from sites of infection is crucial to resolution of inflammation.
Phagocytosis ultimately accelerates apoptosis to promote resolution of the
inflammatory response and return the immune system to quiescence (Fig. 3).

9

Macrophages recognize and remove the effete neutrophils through a process
called efferocytosis (52,74). Most invading microorganisms are eliminated by the

Figure 3. Two possible outcomes of the interaction of PMNs with
bacteria. On one hand, bacteria (pink spheres) are ingested, activate PMNs
and are killed, and this process ultimately triggers PMN apoptosis and the
removal of these cells by macrophages (Efferocytosis). This phenomenon
leads to the resolution of the inflammatory response (RESOLUTION).
Alternatively, bacterial pathogens (yellow spheres or red particles) are
ingested and either delay normal PMN apoptosis and turnover or cause PMN
lysis. Typically, these processes facilitate survival of bacteria and thereby
promote disease (DISEASE). Reprinted with permission from J. Mol. Med.
(52).
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oxygen-independent and oxygen-dependent neutrophil killing mechanisms
described above. Nonetheless, several bacterial pathogens, including S. aureus,
are known to evade neutrophil-mediated killing. Pathogens alter neutrophil
function or survival to evade the innate immune system and thereby promote
disease. As depicted in Fig. 3, some ingested S. aureus survive within the
neutrophil phagosome and eventually cause destruction of the leukocyte (75-77).
Notably, CA-MRSA strains have enhanced capacity to cause destruction of
neutrophils compared to representative HA-MRSA strains (78). These findings
provide support to the idea that the most prominent CA-MRSA strains are highly
virulent as a result of enhanced ability to escape the antimicrobial activity of
neutrophils following phagocytosis.
S. aureus produces many molecules that potentially contribute to evasion
of the innate immune system, including pore-forming toxins that permeabilize
leukocyte plasma membranes (55,79-81). PVL is one such pore-forming toxin
and is present in USA300, USA400, and other S. aureus strains that are a
prominent cause of CA-MRSA infections (52,82). For this reason, significant
effort has been made by the infectious disease community to elucidate the role (if
any) PVL has in CA-MRSA pathogenesis (52,82).

1.2 Panton-Valentine leukocidin

1.2.1 Panton-Valentine leukocidin (PVL), a bicomponent pore-forming toxin

11

The observation that PVL is associated with the major CA-MRSA lineages
suggests that the toxin may enhance strain virulence or promote enhanced
transmission (30,39, 83,84). Characterization of the cytolytic activity of PVL
began in 1932 (as described by Panton and Valentine) (85), and thus, PVL was
present in S. aureus long before the emergence of CA-MRSA. Studies published
in 2002 indicate PVL is associated with fatal S. aureus necrotizing pneumonia,
usually with antecedent influenza (83). These findings, coupled with the
coincident emergence of CA-MRSA worldwide, renewed interest in PVL as a
major S. aureus virulence factor. More recently, studies have confirmed an
association of community-associated S. aureus pneumonia (MRSA and
methicillin-susceptible S. aureus or MSSA) with antecedent influenza or an
influenza-like illness (86-88). The molecular basis for severe S. aureus
pneumonia following influenza remains unknown.
PVL consists of two subunits, LukS-PV and LukF-PV, both of which are
secreted as water soluble monomers. The crystal structure of LukF-PV (89) and
LukS-PV (90) has been solved and each subunit has three regions, the betasandwich, the rim, and the folded stem. The LukS-PV subunit binds to the
surface of rabbit and human neutrophils, monocytes, and macrophages (56-59).
Following LukS-PV binding, a hypothetical pre-pore octomer is formed on the
PMN plasma membrane with both subunits present in a 1:1 ratio (Fig. 4). At this
point, the rim regions of LukF-PV and LukS-PV interact with the neutrophil
plasma membrane. Large variations in conformation between the two subunits
are present in the rim (90). Presumably, functional differences between the two
12

PVL subunits are determined by variances in the rim domain. Complete poreformation is accomplished by extension of the stem region of both subunits
through the plasma membrane, forming a beta-barrel (Fig. 4) (89-93).
Genes encoding PVL, lukS-PV and lukF-PV, are acquired by horizontal gene
transfer via
bacteriophage such as
Figure 4. Proposed
mechanism for PVL
pore formation. A)
LukF-PV (red oval) and
LukS-PV (tan oval) are
secreted as soluble
monomers. B) LukS-PV
binds to an unidentified
surface molecule/
receptor on the surface
of myeloid cells,
including neutrophils or
PMNs. C) PVL subunits
associate in a 1:1 ratio
until eight subunits form
a hypothetical pre-pore
on the myeloid cell
surface. D) The stem
region of each subunit
extends through the
plasma membrane to
form an octomeric betabarrel pore.

phiSA2usa and the
subunits are cotranscribed as an operon
(94,95). A recent study
reported the entire
nucleotide sequence of
lukS/F-PV prophages
from 114 clinical MRSA
isolates and identified
two insertion sites in the
S. aureus genome (Ins1
and Ins2) (96). The
insertion sites are
singularly present and

either Ins1 or Ins2 occur in specific MRSA lineages. The PVL nucleotide
sequence is highly conserved and one genetic polymorphism in lukS-PV results
in a nonsynonymous amino acid change in LukS-PV. Variants containing an
13

arginine (R variant) or a histidine (H variant) are segregated into specific
geographic regions. USA300 expresses the R variant, and therefore this variant
is prominent in the US (97). Studies comparing the interaction of PMNs with R
and H variants of PVL determined that this amino acid substitution has no impact
on PVL activities that are described in greater detail below (98,99).

1.2.2 Panton-Valentine Leukocidin (PVL) and human neutrophil interaction
The potential for PVL to alter neutrophil function or cause cytolysis is of
particular interest because PMNs represent the first line of host defense against
S. aureus infection (60,61,81). Lytic activity of PVL is concentration-dependent
(58,100-102) and a concentration threshold of PVL must be reached for lysis of
PMNs to occur. Levels of the toxin below this concentration threshold, estimated
at 0.2-6 nM, are sublytic (100). Neutrophils exposed to sublytic levels of purified
PVL exhibit numerous cellular responses that require the presence of both PVL
subunits. A Ca2+ influx that requires extracellular calcium precedes the formation
of pores in the plasma membrane (58,59). These two events, Ca2+ influx and
pore formation, are both mediated by PVL; however, they are induced by distinct
cellular mechanisms (103). PMNs exposed to sublytic levels of PVL in the
presence of Ca2+ release several proinflammatory molecules, such as interleukin8 (IL-8) and leukotreine B4 (62,104-106). Transcription of IL-8 is upregulated
following incubation of PMNs with sublytic concentrations of PVL (105). These
findings support the notion that the presence of Ca2+ is essential for PVLmediated release of proinflammatory molecules from human neutrophils. Further,
14

Ca2+ entry into the host cell requires exposure of neutrophils to both PVL
subunits (90,92). PVL also induces granule exocytosis, thereby releasing
myeloperoxidase, lysozyme, and beta-glucuronidase into the extracellular space
(106,107). Although granule exocytosis is consistent with PMN priming, PVL
alone causes limited production of ROS by human neutrophils (106,108).
However, neutrophils incubated with PVL and then activated with fMLP released
3-4 times more ROS compared to neutrophils exposed to PVL alone (108). This
observation indicates that sublytic levels of PVL prime neutrophils for enhanced
activation by a secondary stimulus.
Downstream signal transduction pathways induced or inhibited by the
interaction of neutrophils with PVL remain largely uncharacterized, although a Gprotein coupled receptor has been previously implicated in the process (109).
The finding that PVL oligomers associate with neutrophil lipid rafts coupled with
the observation that inhibition of protein tyrosine kinases decreases PVLmediated IL-8 release, supports the notion that PVL triggers neutrophil signal
transduction (105,110).

1.3 Contribution to the field

Although the lukS/F-PV operon is present in many strains that cause CAMRSA infections including the epidemic USA300 clone (39,84), the finding is not
universal. In addition, multiple studies indicate that the presence of PVL is not a
primary determinant of the clinical outcome of S. aureus infections (111-114).
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Bae et al. actually found that patients with PVL-positive infections were more
likely cured after treatment compared to those with PVL-negative infections
(113). These findings highlight the need to re-evaluate the role played by PVL
during S. aureus infection.
PVL-positive strains express differential amounts of PVL during growth in
vitro or in vivo (115-118). Human abscesses caused by PVL-positive strains were
analyzed for presence of PVL and expression of 0.27-2 µg/ml of PVL was
detected in 15 samples (117). A subsequent study screened 72 methicillinsensitive and methicillin-resistant clinical specimens (lukS/F-PV-positive) for PVL
expression (118). Eighty-six percent of the lukS/F-PV-positive isolates (62/72
samples) secreted 0-3 µg/ml of PVL during infection. Thus, it is unlikely that a
concentration of PVL necessary for cytolysis is attained in vivo during infection,
except perhaps at the focus of infection.
The overarching objective of my dissertation research is to better
understand the role played by PVL during the interaction of CA-MRSA with the
host. One hypothesis is that PVL causes cytolysis of PMNs, thereby enhancing
S. aureus virulence. As a step toward testing this hypothesis, we evaluated
human neutrophil pore formation and cytolysis using USA300 and USA400
culture supernatants from multiple S. aureus growth conditions in vitro or purified
PVL, and determined whether there was a direct correlation between pore
formation and subsequent cytolysis (Chapter 2).
The level of PVL produced in vivo may not be sufficient to cause lysis of
PMNs. However, it is possible that sublytic levels of PVL alter the host response
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to infection. For example, animal infection studies with wild-type (WT) and
isogenic lukS/F-PV deletion strains suggest that PVL increases the innate
immune response, and thereby augments clearance of infection. We hypothesize
that PVL primes PMNs for enhanced function, thus altering the outcome of CAMRSA infection. To test this hypothesis, we investigated the ability of sublytic
concentrations of PVL to prime human neutrophils for enhanced function
(Chapter 3). In addition, we assessed global changes in PMN gene expression
and identified proinflammatory molecules released from neutrophils following
exposure to a sublytic concentration of PVL (1 nM). These results, in combination
with previous studies, suggest PVL functions primarily as an immune modulatory
agent rather than a cytolytic toxin.
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CHAPTER TWO
RELATIVE CONTRIBUTION OF PANTON-VALENTINE LEUKOCIDIN TO PMN
PLASMA MEMBRANE PERMEABILITY AND LYSIS CAUSED BY USA300 AND
USA400 CULTURE SUPERNATANTS
2.1 Abstract
Panton-Valentine leukocidin (PVL) is a cytolytic toxin associated with
severe community-associated methicillin-resistant Staphylococcus aureus (CAMRSA) infections. However, the relative contribution of PVL to host cell lysis
during CA-MRSA infection remains unknown. Here we investigated the relative
contribution of PVL to human polymorphonuclear leukocyte (PMN) plasma
membrane permeability and lysis in vitro by using culture supernatants from wildtype and isogenic lukS/F-PV-negative (Δpvl) USA300 and USA400 strains.
Using S. aureus culture conditions that favor selective high production of PVL
(CCY media), there was on average more PMN plasma membrane permeability
and cell lysis caused by supernatants derived from wild-type strains compared
with those from Δpvl strains. Unexpectedly, plasma membrane permeability did
not necessarily correlate with ultimate cell lysis. Moreover, the level of pore
formation caused by culture supernatants varied dramatically (e.g., range was
0.32–99.09% for wild-type USA300 supernatants at 30 min) and was not
attributable to differences in PMN susceptibility to PVL among human blood
donors. We conclude that PMN pore formation assays utilizing S. aureus culture
supernatants have limited ability to estimate the relative contribution of PVL to
pathogenesis (or cytolysis in vitro or in vivo), especially when assayed using
culture media that promotes selective high production of PVL.
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2.2 Introduction
Staphylococcus aureus is a significant cause of human infections worldwide.
The organism also acquires antibiotic resistance readily and methicillin resistant
S. aureus (MRSA) are endemic in healthcare settings in many countries (1).
Prior to the early 1990s, MRSA infections were almost exclusively associated
with healthcare settings and disease occurred in individuals with known risk
factors for infection. Although healthcare-associated MRSA (HA-MRSA) remain
a major problem, MRSA are a leading cause of community-associated bacterial
infections in some industrialized countries, such the United States and Canada
(2). These so-called community-associated MRSA (CA-MRSA) infections occur
in seemingly healthy individuals with no predisposing risk factors for infection,
suggesting that they have enhanced virulence by comparison. Experimental
data with animal infection models using CA-MRSA strains provides strong
support to this notion (3,4). The molecular basis for the enhanced virulence
phenotype of CA-MRSA strains, especially USA300 and USA400, which
predominate in North America, is incompletely defined.
A methicillin-resistance element known as staphylococcal cassette
chromosome (SCC) mec type VI (SCCmecIV) and genes encoding PantonValentine leukocidin (PVL) (lukS-PV and lukF-PV) are elements common among
many CA-MRSA strains worldwide (2). PVL is a cytolytic toxin composed of
LukF-PV and LukS-PV subunits that assemble into an octameric pore on the
surface of myeloid cells, including polymorphonuclear neutrophils (PMNs).
Although sublytic concentrations of PVL cause PMN apoptosis (5), sufficient pore
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formation causes a change in the cellular levels of normally impermeable solutes,
such as K+, which can lead to osmotic cell lysis (necrosis) (6,7). The leukocidin
is linked by epidemiology to specific types of severe skin infection and severe
necrotizing pneumonia (8,9). Inasmuch as PMNs are the primary cellular
defense against S. aureus infections, molecules such as PVL that have potential
to eliminate neutrophils and/or alter neutrophil function might therefore contribute
to pathogenesis. USA300 and USA400 strains contain genes encoding multiple
pore-forming toxins with high homology or identity to lukS-PV and lukF-PV. The
relative contribution of these molecules to CA-MRSA virulence has not been
determined, although this matter has been the subject of intense research over
the past several years (10-15). In addition, high expression of PVL in vitro
appears optimal only during growth in specific S. aureus culture media, which
may limit the utility of such assays in predicting activity in vivo.
As a step toward understanding the relative contribution of PVL to lysis of
PMNs caused by USA300 and USA400 strains, we evaluated human PMN
plasma membrane permeability and lysis using culture supernatants from
multiple S. aureus growth conditions in vitro.

2.3 Materials and Methods
2.3.1 Bacterial strains and culture.
USA300 (LAC and SF8300) and USA400 (MW2) wild-type and isogenic
lukS-PV and lukF-PV deletion strains (LACΔpvl, SF8300Δpvl, and MW2Δpvl)
were described previously (11,12). Bacteria from frozen, low passage stocks
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were cultured overnight in trypticase soy broth (TSB, Difco, Detroit Michigan),
CCY medium (3% wt/vol yeast extract, 2% Bacto-Casamino acids, 2.3% sodium
pyruvate, 0.63% Na2HPO4, and 0.041% KH2PO4, pH 6.7), or 100% pooled
human serum. Overnight cultures were either used to generate supernatants
directly or diluted 1:200 into fresh culture media and incubated for 8 h (to early
stationary phase of growth, OD600 = 0.75) with shaking at 225 rpm at 37°C.
Bacteria were removed from the culture media by centrifugation (2061 g for 10
min at 4°C). Culture supernatants were sterilized by filtration and stored in
aliquots at -80°C for future use.

2.3.2 Purification of PVL subunits from USA300 culture medium.
LukS-PV and LukF-PV subunits were purified from culture supernatants of
USA300 strain LAC containing deletion of hlgA, hlgB, and hlgC (LACΔhlgABC)
as described previously (16,17), but with a few modifications. Briefly,
LACΔhlgABC was cultured to early stationary phase of growth in CCY medium
and cultures were centrifuged to remove bacteria. Following sterile filtration,
supernatant proteins were precipitated with ammonium sulfate (80% saturation)
at 4°C for 16 h. Precipitates were centrifuged at 15000 g for 20 min at 4°C and
resuspended in Buffer 1 (30 mM sodium phosphate buffer, pH 6.5). Proteins
were dialyzed against Buffer 1 for 5 h, subjected to ion-exchange
chromatography using a HiPrep 16/10 CM FF sepharose column (GE Healthcare
Life Sciences, Piscataway, New Jersey), and eluted with a linear gradient of 0 to
0.5 M NaCl in Buffer 1. Fractions containing LukS-PV were subjected to a
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second round of ion-exchange chromatography using a Mono S 5/50 GL column
(GE Healthcare Life Sciences) and LukS-PV was eluted with a linear gradient of
0 to 0.25 M NaCl in Buffer 1. Ammonium sulfate was added to LukF-PV and
LukS-PV fractions to 1.5 M and these samples were subjected to hydrophobic
interaction chromatography using a HiTrap Butyl HP column (GE Healthcare Life
Sciences). PVL subunits were eluted with a linear gradient of 1.5 to 0 M
ammonium sulfate and aliquots of each subunit were stored at -80°C in 0.2 M
NaCl-Buffer 1. Identity and purity of LukS-PV and LukF-PV were evaluated
initially by SDS-PAGE and immunoblot analysis, and then by liquid
chromatography tandem mass spectrometry (LC-MS/MS) at the NIAID Mass
Spectrometry Unit, Bethesda, Maryland.

2.3.3 Human PMN assays.
PMNs were isolated from venous whole blood of healthy individuals using a
published method (18) in accordance with a protocol approved by the NIAID
Institutional Review Board for Human Subjects. Each human subject included in
the study gave informed consent. Lysis of PMNs was assessed by the release of
lactate dehydrogenase (LDH) using a Cytotoxicity Detection Kit (Roche Applied
Sciences, Pleasanton, California) as described previously (3,12). Culture
supernatants were thawed on ice and diluted in RPMI 1640 medium (Invitrogen)
buffered with 10 mmol/l HEPES (RPMI/H, pH 7.2). PMNs (1 × 106) in 100 µl
RPMI/H were combined with 100 µl of diluted supernatants in 96-well roundbottom plates. Cells were incubated for the indicated times (3-18 h) at 37°C with
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5% CO2. At designated time points, plates were centrifuged at 587 g for 7 min at
4°C. Aliquots (100 µl) from each well were transferred to a 96-well flat-bottom
plate and percent LDH release was determined according to the manufacturer’s
instructions.
PMN plasma membrane permeability (formation of plasma membrane
pores) was measured by ethidium bromide (EtBr) uptake as described essentially
by Gauduchon et al. (19). Culture supernatants were diluted in RPMI/H as
described above and mixed 1:1 with human PMNs (1 × 106) and 4 µmol of EtBr
as described (19). At designated time points, PMNs were analyzed by flow
cytometry (FACSCalibur, BD Biosciences, San Jose, California).
In some experiments, PMNs were incubated with 1 nM purified PVL
(LukS-PV + LukF-PV) or individual PVL subunits and EtBr and LDH release were
determined as described above.

2.3.4 SDS-PAGE and LukS/F-PV Western Blots.
Proteins present in CCY and TSB culture supernatants were resolved by
12.5% SDS-PAGE and transferred to nitrocellulose membranes using an iBlot
Dry Blotting System (Invitrogen, Carlsbad, California). Nitrocellulose membranes
were blocked in Tris-buffered saline containing 10% goat serum and 1% Tween
20 overnight. Immunoblots were rotated for 1 h at ambient temperature in diluted
blocking buffer containing affinity-purified rabbit IgG specific for a peptide region
of LukF-PV or LukS-PV (GenScript USA Inc., Piscataway, New Jersey) or rabbit
IgG specific for Hla (Sigma-Aldrich, St. Louis, Missouri). Membranes were
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washed three times for 10 min each in wash buffer (250 mM NaCl, 10 mM
HEPES, 0.2% Tween-20, pH 7.4) and then incubated with peroxidaseconjugated anti-rabbit donkey IgG secondary antibody for 1 h. Membranes were
washed twice in wash buffer and once in Tris-buffered saline and LukF-PV and
LukS-PV were visualized using enhanced chemiluminescence (SuperSignal
West Pico, Fisher Scientific, Pittsburg, Pennsylvania). LukS-PV was quantified
by densitometry with a standard curve of purified LukS-PV using Quantity One
Software (Bio-Rad Laboratories, Hercules, California). There was 0.8 µg/ml, 3.8
µg/ml, and 3.6 µg/ml LukS-PV produced by MW2, LAC, and SF8300 in TSB at
early stationary phase of growth, and 0.9 µg/ml, 2.0 µg/ml, and 1.2 µg/ml for
these strains after overnight growth in the same media. By comparison, there
was 30.6 µg/ml, 100.4 µg/ml, and 101.4 µg/ml LukS-PV produced by MW2, LAC,
and SF8300 in CCY at early stationary phase of growth, and 31.8 µg/ml, and
32.8 µg/ml for LAC and SF8300 after overnight growth in CCY. PVL subunits
were frequently not detectable in MW2 culture supernatants after overnight
growth in CCY.

2.3.5 S. aureus genomic DNA extraction.
USA300 strain LAC was cultured in TSB to early stationary phase of
growth and then bacteria were pelleted by centrifugation as described above.
Bacteria were resuspended in 450 µl of P1 buffer (Plasmid Prep Kit, Qiagen, Inc.,
Valencia, California), to which 50 µl of 1 mg/ml lysostaphin was added. Samples
were incubated for 3 h at 37°C to complete lysis. After lysis of bacteria, DNA
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was isolated using the DNeasy Tissue Kit (Qiagen) and as recommended by the
manufacturer.

2.3.6 RNA extraction and TaqMan Real-Time RT-PCR analysis.
S. aureus strains were cultured as indicated and lysed using FastPrep (FP
120, MP Biomedicals, Solon, Ohio). RNA isolation was completed using the
RNeasy Mini Prep Kit (Qiagen) as described previously (20). Each strain and
growth condition was assayed in triplicate by TaqMan real-time RT-PCR analysis
using an ABI 7500 thermocycler (Applied Biosystems Inc., Foster city, California).
Change in expression of target genes was determined by comparison to known
quantities of S. aureus genomic DNA and relative expression of the
housekeeping gene gyrB. The primer-probe sequences are as follows: gyrB
forward primer 5’-CAAATGATCACAGCATTTGGTACAC-3’, gyrB probe 5’-AATC
GGTGGCGACTTTGATCTAGCGAAAG-3’, gyrB reverse primer 5’-CGGCATCAG
TCATAATGACGAT-3’, LukF-PV forward primer 5’-TTGCTTTTGCTATCCAATAC
AGTTG-3’, LukF-PV probe 5’-TGCAGCTCAACATATCACACCTGTAAGT-3’,
LukF-PV reverse primer 5’-TCGGAATCTGATGTTGCAGTTG-3’, LukS-PV
forward primer 5’-AATAACGTATGGCAGAAATATGGATGT- 3’, LukS-PV probe
5’-ACTCATGCTACTAGAAGAACAACACACTATGG-3’, LukS-PV reverse primer
5’-CAAATGC GTTGTGTATTCTAGATCCT-3’.

2.3.7 Statistical analyses.
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Data were evaluated using a paired Student’s t-test (GraphPad Prism 5,
GraphPad Software, Inc., San Diego, California). PMN lysis data in Fig. 7 from
wild-type CCY culture supernatants were also compared using a one-way
analysis of variance (ANOVA) and Tukey’s posttest.

2.4 Results
2.4.1 Membrane pore formation caused by S. aureus culture supernatants is
highly variable.
To estimate the relative contribution of PVL to formation of membrane
pores in leukocytes, we evaluated the ability of culture supernatants from
USA300 and USA400 wild-type and Δpvl strains to promote uptake of ethidium
bromide (EtBr) by human PMNs (Fig. 5 and 6). EtBr uptake has been used
widely to estimate PVL-mediated membrane pore formation with human
neutrophils, as the diameter of the pores (2–2.4 nm or 20-24 angstroms) allow
free diffusion of EtBr (0.8 nm or 8 angstroms) into cells (21-26). We first tested
pore-forming capacity of CCY culture supernatants, since S. aureus can produce
up to 100 milligrams of PVL per liter of CCY media (16,27,28). There was timedependent formation of PMN membrane pores with all growth conditions and
supernatant concentrations (dilutions) tested (Fig. 5 and 6). On average, there
was significantly more uptake of EtBr by PMNs exposed to wild-type culture
supernatants compared with those from Δpvl strains (Fig. 5 and 6). However, in
many of the individual assays, especially those in which PMNs were exposed to
culture supernatants for 30 min, the level of pore formation was comparable
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Figure 5. Permeability of PMNs (plasma membrane pore formation)
exposed to USA300 and USA400 CCY culture supernatants. PMNs (1
× 106) were incubated with a 1:500 dilution of CCY media alone (CCY) or
CCY culture supernatants obtained from growth of S. aureus strains as
indicated. Each symbol indicates a separate experiment and/or human
PMN donor. Different batches of CCY media are indicated by symbol color
or fill. Black bars indicate the mean percent ethidium bromide (EtBr) uptake
by PMNs at each time point, A) 5 min. B) 15 min. C) 30 min. *: p ≤ 0.05 vs.
wild-type (WT; i.e., MW2, LAC, or SF8300); **: p ≤ 0.01 vs. WT; ***: p ≤
0.001 vs. WT.
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Figure 6. Permeability of PMNs exposed to USA300 and USA400 CCY
culture supernatants. PMNs (1 × 106) were incubated with a 1:2000
dilution of CCY media alone (CCY) or CCY culture supernatants obtained
from growth of S. aureus strains as indicated. Each symbol indicates a
separate experiment and/or human PMN donor. Different batches of CCY
media are indicated by symbol color or fill. Black bars indicate the mean
percent ethidium bromide (EtBr) uptake by PMNs at each time point, A) 5
min. B) 15 min. C) 30 min. *: p ≤ 0.05 vs. wild-type (WT; i.e., MW2, LAC, or
SF8300); **: p ≤ 0.01 vs. WT; ***: p ≤ 0.001 vs. WT.
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between wild-type and Δpvl strains (Fig. 5B and C, and Fig. 6C). We found that
culture supernatants from bacteria grown in trypticase soy broth (TSB), a
standard culture medium for S. aureus, had little or no PMN pore-forming
capacity at the highest concentration used for CCY (1:500 dilution) (data not
shown). Membrane pore formation was highly varied using CCY culture
supernatants (e.g., the range of pore formation was 0.6–99.9% for the MW2 wildtype strain at 30 min using a 1:500 dilution) (Fig. 5C). Although there was
variation in PMN pore formation among individuals using the same batch of
culture supernatant, some of the observed variation overall was due to
differences among separate batches CCY media (Fig. 5 and 6, symbol colors
and fills).

2.4.2 Correlation of membrane pore formation and PMN lysis.
Formation of plasma membrane pores by PVL and other two-component
toxins of S.aureus is generally considered to result in host cell lysis. To test this
notion, we evaluated the ability of culture supernatants from USA300 and
USA400 wild-type and Δpvl strains to cause release of lactate dehydrogenase
(cell lysis) from human PMNs over time (Fig. 7 and 8). PMN lysis caused by
exposure to CCY or TSB culture supernatants from USA300 and USA400 strains
was time and concentration dependent (Fig. 7 and 8). In addition, there was
significantly more lysis of PMNs exposed to wild-type CCY culture supernatants
compared with those from Δpvl strains at the highest concentrations tested
(1:250 and 1:500 dilutions) (Fig. 7A and B). In contrast, there was no difference
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Figure 7. PMN lysis after exposure to USA300 or USA400 CCY
culture supernatants. PMNs (1x106) were incubated for 3, 6, 9, or 18
h with the indicated dilution of culture supernatant. Cell lysis was
measured by LDH release as described in Materials and methods. Bars
indicate mean ± SD of 8-11 PMN donors; *p ≤ 0.05 vs. WT; #p ≤ 0.05
using a one-way analysis of variance (ANOVA) with a Tukey’s posttest.
A) 1:250 dilution. B) 1:500 dilution. C) 1:2000 dilution. PVL ‘‘+’’
indicates wild-type lukS/F-PV positive strain; PVL ‘‘-’’ indicates isogenic
lukS/F-PV negative strain. CCY alone caused no significant lysis of
human PMNs over the 18 h culture period (range was 0-1.5% for 3-18
h, n = 4 PMN donors).
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Figure 8. PMN lysis after exposure to USA300 or USA400 TSB culture
supernatants. PMNs (1x106) were incubated for 3, 6, 9, or 18 h with the
indicated dilution of culture supernatant. Cell lysis was measured by LDH
release as described in Materials and methods. Bars indicate mean ± SD of
6 PMN donors for panels A-C and 4-6 PMN donors for panel D; *p ≤ 0.05
vs. WT. A) 1:10 dilution. B) 1:50 dilution. C) 1:100 dilution. D) 1:500 dilution.
PVL ‘‘+’’ indicates wild-type lukS/F-PV-positive strain; PVL ‘‘-’’ indicates
isogenic lukS/F-PV negative strain. TSB alone caused no significant lysis of
human PMNs over the 18 h culture period (range was 0-0% for 3-18 h, n =
4 PMN donors).
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in PMN lysis between TSB culture supernatants from wild-type and Δpvl strains
(e.g., PMN lysis was 87.1 ± 14.5 and 87.5 ± 9.1% after a 3-h exposure to LAC
wild-type and Δpvl TSB supernatants from overnight culture (1:10 dilution) (Fig.
8).
Although there was some concordance between pore formation and cell
lysis assays, especially with CCY culture supernatants from wild-type strains,
there were noted differences. First, at the lowest concentration of CCY culture
supernatant used (1:2000 dilution), there was little or no correlation between pore
formation and PMN lysis (compare Fig. 6C and 7C). Further, PMN pore
formation was at or near 100% after 30 min of exposure to the highest
concentration of CCY culture supernatants from Δpvl strains (Fig. 4C), whereas
the corresponding cell lysis was < 10% at all time points tested (up to 18 h) (Fig.
7B). We also note that culture supernatants from the MW2 wild-type strain often
caused significantly less lysis than those from USA300 wild-type strains (Fig. 7).
Collectively, the data indicate that pore formation caused by S. aureus culture
supernatants does not necessarily correlate with (or result in) cell lysis.
Inasmuch as in vitro culture media (CCY and TSB) are not likely
representative of culture conditions during infection in humans, we tested the
ability of normal human serum to promote production and activity of S. aureus
cytolytic toxins. In contrast to CCY and TSB, human serum used as culture
media for USA300 and USA400 strains had zero capacity to cause PMN lysis at
all concentrations tested (1:1–1:100 dilutions). This finding cannot be explained
by the absence of bacterial growth in serum, since S. aureus grew reasonably
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well in this culture substrate (Fig. 10H). Rather, the lack of PMN cytolysis in
serum culture supernatants may be due to the ability of serum lipoproteins and
apolipoprotein B to inhibit agr signaling (29), a regulator of expression of multiple
virulence factors, and thus, synthesis and secretion of PVL.
Figure 9. Purified PVL
causes relatively
consistent levels of
plasma membrane pore
formation in human
PMNs. A-C) PMNs
(1x106) were incubated
with 1 nM of purified PVL
subunits (LukF-PV or
LukS-PV) or the
combination of both
subunits for the indicated
times. Each symbol color
indicates a separate
human PMN donor (n =
9). Black bars indicate the
mean percent ethidium
bromide (EtBr) uptake by
PMNs at each time point.
D) PMNs (1x106) were
incubated with 1 nM of
purified PVL subunits
(LukF-PV or LukS-PV)
and PMN lysis was
measured by release of
LDH as described in
Materials and methods.
Red bar indicates mean ±
SD of 4 PMN donors.
2.4.3 Cytolytic effects of purified PVL and human blood donor variability.
We next used PVL subunits purified from USA300 to determine whether
the variation in PMN pore formation noted in the assays with culture supernatant
was due to individual susceptibility to PVL (Fig. 9). Neither subunit alone caused
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formation of membrane pores in human PMNs. By comparison, there was timedependent uptake of EtBr using the combination of 1 nM LukF-PV+LukS-PV (Fig.
9). There was far less variation in the capacity of purified PVL to permeabilize
human PMNs compared with culture supernatants (EtBr uptake was 76.1–96.1%
at 30 min using purified PVL subunits) (Fig. 9C). Despite the high level of pore
formation, there was essentially no corresponding PMN lysis at this time point
(LDH release was 0.7 ± 0.7% at 30 min, n = 4 PMN donors) (Fig. 9D). These
data indicate that the variation noted in assays with culture supernatants is
largely independent of differences in PMN donor susceptibility to PVL.

2.4.4 Levels of lukS-PV and lukF-PV transcript and corresponding PVL protein
subunits are highly varied depending on in vitro growth conditions.
We next compared levels of lukS-PV and lukF-PV (lukS/F-PV) transcripts
and corresponding protein subunits following culture of USA300 and USA400
strains in CCY, TSB, or human serum (Fig. 10A–H). Compared with strains
cultured in TSB or human serum, there was more lukS/F-PV transcript made by
LAC and MW2 following culture in CCY (Fig. 10A–C). In accordance with these
findings, more LukS-PV and LukF-PV accumulated in CCY culture media
compared with that in TSB (Fig. 10D–F). Most notably, there was selective high
production of PVL in CCY media, since the level of alpha-hemolysin (Hla,
another agr-regulated cytolytic toxin) present in CCY was not increased relative
to that in TSB culture supernatants (Fig. 10F). Using a purified PVL standard,
we estimate that USA300 strains accumulated ~3–4 µg/ml of LukS-PV in TSB
54

Figure 10. Impact of culture media on lukS-PV and lukF-PV transcript
levels and protein subunit secretion. A-C) Relative expression of lukSPV and lukF-PV transcripts during bacterial growth as indicated. Different
colors or fill indicate separate batches of CCY. Symbols are the mean of
triplicate TaqMan samples. Black bars indicate mean of each strain
group. A) Growth in CCY. B) Growth in TSB. C) Growth in normal human
serum. D) PVL secretion during growth in CCY (upper panel) or TSB
(lower panel). E) Longer exposure of the immunoblot shown in the lower
panel of D. Results in panels D and E are representative of 3
experiments. F) Immunoblot of PVL subunits (1.75 µl of CCY or TSB
culture supernatants) and Hla (35 µl of CCY or TSB culture supernatants)
produced in CCY or TSB culture at early stationary phase of growth.
Results are representative of 2 experiments. G) Immunoblot of PVL
subunits secreted during MW2 (USA400) and SF8300 (USA300) growth
in different batches of CCY. H) Growth of LAC (USA300) in CCY, TSB,
and normal human serum.
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and ~100 µg/ml in CCY at early stationary phase of growth (see Materials and
Methods for details). The finding that there was little or no detectable lukS/F-PV
transcript made by LAC cultured in human serum (Fig. 10C) is consistent with the
observation that supernatants from neither USA300 nor USA400 strains cultured
in human serum caused PMN lysis (data not shown) and that serum lipoproteins
inhibit agr signal transduction (29).
There were also strain-dependent differences in lukS/F-PV transcript and
PVL protein levels. For example, compared with LAC, there was less lukS/F-PV
transcript made by MW2 in either CCY or TSB, and there was correspondingly
less accumulated PVL protein in MW2 culture supernatants (e.g., there was ~42fold more lukF-PV transcript made by LAC at early stationary phase of growth in
CCY compared with MW2) (Fig. 10). These findings are compatible with
differences noted between USA300 and USA400 strains in recent studies by
Montgomery et al. (30). Although differences in lukS/F-PV transcript and PVL
protein levels may account in part for the differences in PMN lysis observed
between MW2 and USA300 CCY culture supernatants (Fig. 7), there is limited
correlation of transcript and protein levels with pore-forming capacity of the
strains, which was comparable (Fig. 5 and 6). Taken together, these data
provide strong support to the notion that factors present in culture supernatants
other than PVL are sufficient to cause formation of membrane pores in human
PMNs.

2.5 Discussion
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It has long been known that PVL is cytolytic for myeloid cells and therefore, a
putative virulence molecule of S. aureus (31-34). Finck-Barbançon et al.
provided direct evidence that PVL is a pore-forming toxin and reported that
membrane pore size is dictated by ionic conditions of the extracellular
environment (21). Notably, these studies set a precedent for using an ethidium
bromide uptake assay to evaluate membrane permeability following exposure to
PVL (21). Plasma membrane pores that allow ethidium bromide uptake by PMNs
are in general considered to result ultimately in cell lysis through osmotic
imbalance (6,7,21,25). The assay or modifications thereof have since been used
to evaluate precise kinetics of pore formation caused by purified or recombinant
PVL (19,23), pore-forming capacity of heterologous combinations of LukS and
LukF proteins (PVL, gamma-hemolysin, and LukD and LukE subunits) (24), the
ability of intravenous immunoglobulin or specific anti-PVL antibody to block pore
formation (19), and to estimate the relative contribution of PVL to cytolytic
capacity of S. aureus culture supernatants (12,19,35).
We reported previously that PMNs exposed to supernatants from Δpvl strains
cultured overnight in YCP media, a culture media similar in composition to CCY,
promoted uptake of EtBr at levels comparable to the wild-type strains (12).
Although these findings were unexpected, especially given the high level of PVL
produced in either YCP or CCY media (up to 20% of the protein in culture filtrates
(27)), they are perhaps explained by the high variation reported here as intrinsic
to the pore formation assay. Some of the variation is due to differential levels of
lukS/F-PV transcript and PVL protein levels produced in separate batches of the
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same media (Fig. 10A and G). Most importantly, there is not a direct correlation
between EtBr uptake and LDH release by human PMNs, which is a widely
accepted determination of cell lysis.
There is clearly more PMN lysis caused by CCY supernatants from wild-type
USA300 strains compared to that from Δpvl mutant strains (not observed with
MW2 wild-type and Δpvl strains), but this difference is presumably due to the
very high concentration of PVL in CCY culture supernatants. Therefore, diluting
CCY culture media to obtain PVL-specific cytolysis is in essence similar to using
purified PVL, since such an approach decreases the level of other S. aureus
molecules that would have otherwise contributed to pore formation and/or lysis.
This notion is consistent with the observation that there are limited differences in
PMN pore formation between wild-type and Δpvl strains using lower dilutions of
CCY culture supernatant (Fig. 5C), and the finding that PVL is selectively
overproduced in CCY media relative to Hla (Fig. 10F). Furthermore, the
concentration of PVL produced in TSB (3-4 µg/ml), which is more representative
of that found in human abscesses (0.3–1.8 µg/ml) (36), is perhaps a better gauge
of the relative contribution of PVL to PMN lysis caused by S. aureus. In any
case, factors present in TSB culture supernatants other than PVL, such as alphatype phenol-soluble modulins (37) and/or gamma-hemolysin (17), were sufficient
to cause lysis of human PMNs (Fig. 8).
We conclude that the PMN pore formation assays described herein, although
appropriate to evaluate effects of purified PVL or estimate whether cytolytic
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capacity exists in culture supernatant, have limited ability to estimate the relative
contribution of PVL to membrane pore formation or PMN lysis in vivo.
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CHAPTER THREE
SUBLYTIC CONCENTRATIONS OF STAPHYLOCOCCUS AUREUS PANTONVALENTINE LEUKOCIDIN (PVL) ALTER HUMAN NEUTROPHIL GENE
EXPRESSION AND FUNCTION
3.1 Abstract
Community-associated methicillin-resistant Staphylococcus aureus (CAMRSA) infections are often caused by strains encoding Panton-Valentine
leukocidin (PVL). PVL causes lysis of neutrophils and other myeloid cells in vitro,
a function considered widely as the primary means by which PVL might
contribute to disease. However, at sublytic concentrations PVL can function as a
neutrophil agonist. To better understand this phenomenon, we investigated the
ability of PVL at sublytic concentrations (1 nM) to alter human neutrophil function
and survival. PVL-primed neutrophils for enhanced release of superoxide
following activation by fMLP, caused upregulation of CD11b, and accelerated
apoptosis. Priming of neutrophils with other agonists such as IL-8 or GM-CSF
altered the ability PVL to cause formation of pores in the plasma membrane.
Microarray analysis revealed significant changes in the human PMN
transcriptome following exposure to PVL, including upregulation of STAT3,
SOCS3, CXCL1, and CXCL2. Consistent with microarray data myeloperoxidase,
IL-8, IL-6, VEGF, TNFR2, and IL-1RA were released from neutrophils after
stimulation with PVL. We conclude that exposure of human PMNs to sublytic
concentrations of PVL elicits a proinflammatory response that is regulated in part
at the level of gene expression. We propose that PVL-mediated priming of
neutrophils enhances the host innate immune response.

66

3.2 Introduction
Staphylococcus aureus is a Gram-positive bacterium that causes a
significant number of infections worldwide (1). Methicillin-resistant S. aureus
(MRSA) is currently a leading contributor to hospital-acquired (HA-MRSA)
infections (2,3). MRSA infections that occur outside of hospital settings, known
as community-associated MRSA (CA-MRSA) infections, were reported in the
early 1990s and became epidemic in the United States and Canada (4-6). In
contrast to HA-MRSA, CA-MRSA causes infections in individuals with no known
risk factors for infection. The ability of these strains to cause disease in otherwise
healthy individuals suggests that they have enhanced virulence compared to
traditional HA-MRSA strains. In vitro and in vivo work supports this hypothesis (79). Although progress has been made, the molecular basis of the enhanced
virulence phenotype of CA-MRSA remains incompletely determined.
Genes encoding Panton-Valentine leukocidin (PVL) are present in the
genome of many CA-MRSA strains, including the epidemic USA300 strain (1012). PVL consists of two subunits, LukS-PV and LukF-PV, the genes for which
are transcribed as an operon. It is a cytolytic toxin specific for myeloid cells,
including polymorphonuclear leukocytes (PMNs or neutrophils). The presence of
both subunits is required for formation of pores within the PMN plasma
membrane (13,14). Neutrophils are the most prominent cellular component of the
innate immune system and thus the primary defense against S. aureus infections
(15). Therefore, it is possible that PVL contributes to virulence by causing lysis of
PMNs and other myeloid cells. However, previous studies have shown that
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cytolysis in vitro requires a concentration of PVL that may not be achieved in vivo
(16,17). Sublytic concentrations of PVL elicit numerous cellular responses,
including release of myeloperoxidase (MPO) and chemotactic molecules such as
interleukin-8 and leukotriene B4 (18-21). PMNs exposed to PVL undergo granule
exocytosis and produce reactive oxygen species (ROS) following stimulation with
fMLP (22). These observations suggest that sublytic levels of PVL prime
neutrophils for enhanced activation by a secondary stimulus. The molecular
basis for PVL-mediated PMN priming remains unknown.
PMNs primed with cytokines or proinflammatory molecules produced by
bacteria have prolonged survival compared to unprimed cells (23-25). By
comparison, sublytic concentrations of PVL accelerate neutrophil apoptosis (26).
Therefore, the observation that PVL primes PMNs for enhanced function and
induces rather than delays apoptosis differentiates PVL-mediated priming from
that induced by other molecules.
To elucidate the molecular basis of PVL-mediated PMN priming, we
measured PMN gene expression following exposure of these cells to sublytic
concentrations of PVL. In addition, we identified proinflammatory molecules
secreted by PMNs following exposure to the leukotoxin. Our results provide new
insight into the role played by PVL during human infection.

3.3 Materials and Methods
3.3.1 Heat-killed USA300 strain LAC.
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USA300 strain LAC was cultured overnight in trypticase soy broth (TSB)
(Difco, Detroit, MI) from frozen bacterial stocks. Overnight cultures were diluted
1:200 in fresh TSB media and cultured to mid-logarithmic growth phase (O.D.600
= 0.75) as described (17). Bacteria were centrifuged at 3000 rpm for 10 min,
washed once with PBS, and centrifuged again to pellet bacteria. The bacterial
pellet was resuspended in RPMI 1640 meida buffered with 10 mM Hepes and
boiled at 95 ˚C for 10 min.

3.3.2 Purification of PVL subunits from USA300 culture supernatant.
PVL subunits (LukF-PV and LukS-PV) were purified from culture
supernatants of a USA300 hlgABC deletion strain (LACΔhlgABC) as described
previously (17). Purified LukF-PV and LukS-PV were aliquoted separately and
stored at -80˚C in 0.2 M NaCl-Buffer 1 (30 mM sodium phosphate buffer, pH 6.5).

3.3.3 Human PMN isolation.
PMNs were isolated from venous whole blood as previously published
(27). Each subject gave informed consent prior to participation in the study. Use
of healthy individuals for collection of blood was approved by the Institutional
Review Board for Human Subjects, NIAID, NIH.

3.3.4 PMN membrane permeability and lysis assays.
Formation of plasma membrane pores was measured by uptake of
ethidium bromide (EtBr) as previously described by Gauduchon et al. (28).
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Purified PVL subunits (LukF-PV and LukS-PV) were diluted at the desired
concentrations in RPMI/H. PVL-mediated pore formation was evaluated by
incubating human PMNs (1 x 106) with 4 µmol of EtBr and 1 nM, 2 nM, or 5nM
active PVL for 30 min. LukF-PV and LukS-PV were boiled at 95 ˚C for 10 min to
produce heat-inactivated PVL (iPVL). iPVL was used as a negative control. EtBr
uptake was analyzed by flow cytometry (FACSCalibur, BD Biosciences, San
Jose, CA).
Human IL-8 and GM-CSF were purchased from eBiosciences (San Diego,
CA). N-formyl-methionyl-leucyl-phenylalanine (fMLP), phorbol myristate acetate

(PMA), and lipopolysaccharide (LPS) were purchased from Sigma Aldrich (St.
Louis, MO). IL-8, GM-CFS, fMLP, PMA, and LPS were diluted in RPMI/H. PMN
agonists, 20 µM IL-8, 100 ng/ml GM-CFS, 1 µM fMLP, 1 µg/ml PMA, 100 ng/ml
LPS, or heat-killed LAC (107 cfu), were added to human PMNs (1 x 106)
suspended in RPMI/H containing 4 µmol of EtBr. Samples were incubated for 30
min at 37 °C. LPS was sonicated at a frequency of 40 kHz in ice water for 15 min
before use (Branson 2200, Danbury, CT). The PMNs were then incubated with 1
nM PVL (LukF-PV and LukS-PV) for the indicated times. EtBr uptake was
assessed by flow cytometry (FACSCalibur).
PMN lysis was determined by lactate dehydrogenase release (LDH) using
the Cytotoxicity Detection Kit (Roche Applied Sciences, Pleasanton, CA) as
previously described (7,29). Human PMNs (100 µl, 1 x 106) were combined with
1 nM, 2 nM, or 5 nM active PVL or iPVL in a 96-well plate (Costar, Corning, NY)
and incubated at 37 ˚C for 3 h (total 200 µl/well). Plates were centrifuged at 1600
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rpm for 7 min at 4 ˚C and 100 µl aliquots of each well were transferred to a new
96-well plate. Percent LDH release was measured and analyzed as instructed by
the manufacturer.

3.3.5 PMN proinflammatory assays.
The release of superoxide (O2-) was measured as previously described by
DeLeo et al. (30) with modifications. PMNs (1 x 107/ml) were incubated at 37 ˚C
for 30 min with fMLP, LPS, IL-8, GM-CSF, active PVL (LukF-PV and LukS-PV),
heat-inactivated PVL (iPVL), or PVL subunits separately at concentrations
described above (priming). Each agonist (1 µM fMLP, 20 µM IL-8, 100 ng/ml GMCSF, or 1 nM PVL final concentration) was aliquoted into wells of a 96-well
microtiter plate before the addition of primed PMNs (1 x 106). LPS is a known
PMN priming agent (31) and was a positive control for PMN priming. Unprimed
PMNs were combined with 1 µg/ml PMA as a positive control for release of O2-.
All wells contained ferricytochrome c (cyt c, Sigma Aldrich) at a final
concentration of 100 µM. All assays were performed in triplicate ± 40 µg/ml
superoxide dismutase (SOD, Sigma Aldrich). O2- production was determined by
measuring the SOD-inhibitable reduction of cyt c at 550 nm for 20 min by using a
microplate spectrophotometer (Synergy MX, Bio Tek, Winooski, VT) as described
(30). Superoxide production was determined using the molar coefficient for cyt c
(32) as described.
Surface expression of CD11b was determined after PMNs (1 x 106) were
exposed to 1 nM PVL for 0, 15, and 30 min at 37 ˚C. After exposure to PVL, cells
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were washed twice with Stain Buffer (BD Biosciences) and incubated on ice for
60 min with a 1:6 dilution of phycoerythrin (PE)-conjugated anti-human CD11b
primary antibody or PE-labeled mouse IgG1 isotype control (BD Biosciences).
PMNs were washed 3 times with Stain Buffer and analyzed by flow cytometry
(FACSCalibur).
Identification of molecules released from human PMNs following
incubation with PVL was performed by Rules Based Medicine (RBM, Austin, TX).
In brief, human PMNs from 4 different blood donors (1 x 107) were incubated ± 1
nM PVL at 37 ˚C for 4 h. Cell suspensions were centrifuged at 1800 rpm for 10
min at 4 ˚C. Supernatants were analyzed by Rules Based Medicine (HumanMAP
v. 1.6) as described (http://www.rulesbasedmedicine.com/productsservices/
human-maps.aspx).

3.3.6 PMN apoptosis assays.
PMNs were exposed to 1 nM PVL or individual PVL subunits (LukF-PV or
LukS-PV) as described above. Apoptosis was determined using published
methods (33,34). PMNs (1 x 104) were analyzed using the Cytospin Octospot
system (Thermo Scientific Shandon, Waltham, MA) as described by the
manufacturer. PMNs were stained with Wright-Giemsa (Sigma Aldrich) and
condensed nuclei were visualized by light microscopy (Zeiss, Axioskop 2 plus,
Thornwood, NY) at x100 magnification. A total of 250 cells were scored from 5
fields of view for each sample. Images were acquired with an AxioCam digital
camera (Zeiss). Alternatively, PMN apoptosis was assessed using a modified
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TUNEL assay (Apo-BRDU Apoptosis Detection Kit, BD Biosciences) as
described by Kobayashi et al. (27).

3.3.7 PMN microarray analysis.
PMNs (1 x 107) in RPMI/H were cultured with 1 nM PVL or iPVL at 37 ˚C
for 30, 60, or 180 min. At each indicated time point, PMNs were lysed with RLT
buffer and RNA was purified and used to generate ≥ 12 µg of biotin-labeled
cRNA target as previously described (27,34). Samples from 3 different PMN
donors were analyzed on HU133+2 GeneChips (Affymetrix, Santa Clara, CA).
cRNA labeling, GeneChip hybridization, and scanning were completed according
to

GeneChip

manufacturer

protocols

(http://media.affymetrix.com/support/

downloads/manuals/expression_analysis _technical_manual.pdf). Gene chip
hybridization and subsequent scanning was performed by the NIAID-RML
Genomics Core Unit at Rocky Mountain Laboratories (Hamilton, MT). Vehicle
controls were analyzed to determine levels of background signal for each donor
at every time point.
Microarray data was normalized using GeneChip Operating Software
(GCOS v1.4). At each time point, PMNs cultured with active PVL were compared
directly to those treated with iPVL and a principal component analysis (PCA) was
performed using Partek Genomics Suite (Partek, Inc., St. Louis, MO). Genes
were defined as differentially expressed if they were significantly different from
the iPVL control (p ≤ 0.01, two-way analysis of variance, ANOVA), changed twofold in expression, and had signal levels above background. The Venn diagram
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was generated using the iVenn program (NIAID Genomics Core Unit, RML,
Hamilton, MT). Analysis of signal transduction pathways was performed with
Ingenuity Pathway Analysis (IPA, Redwood City, CA).

3.3.8 Statistical analysis.
Rules Based Medicine data were evaluated using a Student’s t-test
(Microsoft Office Excel 2007, Microsoft Corporation, Redmond, WA). PMN
apoptosis data in Fig. 11 were assessed using a Student’s t-test (GraphPad
Prism 5, GraphPad Software, Inc., San Diego, California). PMN pore formation
data in Fig. 12 were compared using a one-way analysis of variance (ANOVA)
and Dunnett’s posttest to correct for multiple comparisons (GraphPad Prism 5).

3.4 Results
3.4.1 Sublytic concentrations of PVL alter human neutrophil function.
We first determined the concentration at which PVL from USA300 strain
LAC culture supernatants causes formation of plasma membrane pores but
limited cytolysis (Fig. 11A). By 30 min, greater than 90% of PMNs were EtBrpositive at each of the PVL concentrations tested (pore formation was 93%, 98%,
and 99% for 1 nM, 2 nM, and 5 nM PVL, respectively). PMN lysis was measured
by release of lactate dehydrogenase using conditions identical to the poreformation assays, but incubation time was extended to 3 h (Fig. 11C). Despite
high levels of pore formation with 1 and 2 nM PVL, subsequent cell lysis was
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limited (9 ± 3% and 15 ± 11%, respectively). We note that cell lysis increased
significantly between 2 nM and 5 nM (e.g., lysis was 52 ± 6% using 5 nM PVL).
Heat-inactivated PVL (iPVL) caused no pore formation and had zero cytolytic
capacity (Fig. 11A and C).

Figure 11. Determining concentrations of purified PVL that remain
sublytic. A) Pore formation. PMNs (1 X 106) were incubated with 1 nM, 2 nM,
or 5 nM native or denatured PVL for 30 min and plasma membrane
permeability was evaluated using an ethidium bromide (EtBr) uptake assay.
Each symbol represents a separate experiment and black bars indicate the
mean. iPVL, heat-inactivated PVL. B) PVL purified from USA300. FPLCpurified PVL subunits (LukF-PV = F and LukS-PV = S) from USA300ΔhlgABC
culture supernatants were analyzed by SDS-PAGE. The gel was stained with
GelCode Blue Stain. C) PMN lysis. PMNs (1 X 106) were incubated with 1 nM,
2 nM, or 5 nM native or denatured PVL for 3 h. Lysis was determined by a
standard assay that measures release of lactate dehydrogenase (LDH). Bars
indicate the mean ± SEM of three donors.
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Figure 12. PVL accelerates
PMN apoptosis. A) Nuclear
condensation. PMNs (1 X 106)
were cultured with 1 nM PVL
(LukF-PV + LukS-PV) and
condensed nuclei were scored by
microscopy. Inset, representative
images of PMNs alone (Ctrl) and
PMNs exposed to 1 nM PVL
(+PVL) at 3h. The black arrow
indicates
a
representative
condensed nucleus. B) TUNEL
Assay. TUNEL-positive PMNs
were
determined
by
flow
cytometry using the same culture
conditions as in panel A. Results
from panel A and B are the mean
± SEM of four PMN donors.

We next performed a series of experiments to determine whether sublytic
concentrations of PVL altered human PMN function as reported previously.
Indeed, 1 nM PVL accelerated neutrophil apoptosis (Fig. 12A and B),
observations consistent with previous work by Genestier et al. (26). These
findings were specific for active PVL, since neither PVL subunit alone (LukF-PV
or LukS-PV) altered neutrophil survival.
In accordance with previous studies (22), 1 nM PVL caused enhanced
release of superoxide (O2-) after stimulation with fMLP (Fig. 13A) and
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Figure 13. PVL alters human
neutrophil
function.
A)
Priming for enhanced release
of O2-. PMNs (1 X 106) were
incubated with 1 nM PVL
(LukF-PV + LukS-PV), 1 nM
heat-denatured PVL (iPVL), or
1 nM of individual PVL
subunits (LukF-PV or LukSPV) for 30 min as indicated.
PMNs were incubated for 30
min and then activated with 1
µM
fMLP.
Superoxide
production was measured
using standard assay for
reduction of ferricytochrome c.
Results represent the mean of
four separate experiments. B)
Surface expression of CD11b.
PMNs (1 X 106) were
incubated with 1 nM PVL (+
PVL) or buffer alone (- PVL)
and surface expression of
CD11b was measured by flow
cytometry. C) Quantification of
CD11b surface expression.
Bars indicate the mean
fluorescence (FL2) of four
separate experiments.

upregulation of CD11b at the plasma membrane (Fig. 13B and C). As with other
priming agents (31, 35), PVL failed to elicit O2- production when used subsequent
to fMLP (Fig. 13A). Collectively, these findings are consistent with the ability of
PVL to function as a neutrophil priming agent.

3.4.2 Proinflammatory molecules alter neutrophil susceptibility to PVL.
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Inasmuch as proinflammatory factors typically prime PMNs for enhanced
function, which includes reorganization/redistribution of molecules at the plasma
membrane, proinflammatory stimuli could conceivably influence the outcome of
the PVL-PMN interaction. To test this hypothesis, we expanded our in vitro
assays to include stimulation of human PMNs with multiple proinflammatory
factors and evaluated PVL-mediated pore formation (Fig. 14A and B). Priming
with fMLP or activation with PMA caused a significant decrease in the ability of
PVL to form pores in the PMN plasma membrane (e.g., 48 ± 10% of the fMLP
primed cells were EtBr-positive following exposure to PVL versus 81 ± 12% EtBrpositive cells following exposure to PVL alone) (Fig. 14A). By comparison,
neither LPS nor heat-killed USA300 (HK LAC) altered the ability of PVL to cause
formation of membrane pores. On the other hand, priming of PMNs with IL-8 or
GM-CSF caused a transient but significant increase in pore formation
(e.g., by 15 min 83 ± 5% of the PMNs were EtBr-positive after exposure to IL-8
compared with 65 ± 6% of those incubated with PVL alone, p ≤ 0.01) (Fig. 14B).
These data indicate that remodeling of the neutrophil plasma membrane
following exposure to specific proinflammatory agonists alters the ability of PVL
to interact with PMNs. One possible explanation for these results is that PVL
binds to a PMN receptor whose surface expression changes following exposure
to specific agonists.
We next determined if PVL induces O2- release from PMNs primed with IL8 or GM-CSF (Fig. 15). IL-8 and GM-CSF primed neutrophils for enhanced fMLPmediated O2- release (positive control, open circles) as described previously
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Figure
14.
Proinflammatory
molecules
alter
neutrophil
susceptibility to PVL. A) Pore formation. PMNs (1 X 106) were
cultured with 100 ng/mL LPS, 1 µM fMLP, 20 µM interleukin-8 (IL-8), 1
µg/mL phorbol-12-myristate-13-acetate (PMA), 100 ng/mL granulocytemacrophage colony-stimulating factor (GM-CSF), or heat-killed USA300
S. aureus strain (HK LAC) (LAC, 1:10 bacteria to PMN ratio) for 30 min
in Hepes-buffered RPMI 1640. PMNs were then incubated with 1 nM
PVL and subsequently assayed for EtBr uptake. Each symbol
represents a separate experiment. Colors indicate separate PMN
culture conditions as indicated. Red bars indicate mean percent EtBrpositive PMNs. B) Temporal increase in PMN susceptibility to PVL
following exposure to IL-8 or GM-CSF. ***, p ≤ 0.001 vs. ▲ and **, p ≤
0.01 vs. ▲ using a one-way analysis of variance (ANOVA) with a
Dunnett’s posttest. Ctrl, PMNs + 1 nM PVL (positive control).
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Figure 15. Effects of PVL on PMN superoxide (O2-) release. O2production was determined by reduction of ferricytochrome c as
described in Materials and Methods. Left panel, PMNs were primed with
PVL and then stimulated with IL-8 (blue open circles) or GM-CSF (red
open circles). Alternatively, PMNs were primed with IL-8 or GM-CSF and
then stimulated with PVL (open triangles) or fMLP (closed triangles).
Right panel, assays performed without a secondary stimulus.

(36-38). PVL caused O2- release from IL-8 and GM-CSF primed neutrophils,
albeit 3-4 times less than that caused by secondary stimulation with
fMLP (open triangles). Collectively, these data indicate that the ability of PVL to
interact with human neutrophils is dictated by the activation state of the cell, and
thus the interaction is specific to some degree.

3.4.3 PVL induces global changes in PMN gene expression.
To gain insight into the molecular basis of PVL-mediated neutrophil
priming, we measured global changes in PMN gene expression following
exposure to 1 nM PVL (Fig. 16 and 17). The number of differentially expressed
genes increased in a time-dependent manner (there were 397 differentially80

expressed genes at 30 min, 1074 differentially-expressed genes at 60 min, and
2850 differentially-expressed genes at 180 min) (Fig. 16). Differentially-

Figure 16. PVL causes global changes in PMN gene
expression. PMNs (1 X 107) were cultured with 1 nM native or
heat-inactivated PVL and changes in transcript levels between the
two conditions were measured using Affymetrix HU133+2
GeneChips as described in Materials and Methods. Venn diagram
depicting the total number of differentially expressed genes at each
time point.

expressed genes were categorized into biological pathways or grouped
according to function using IPA software (Fig. 17). Only 9 signal transduction
pathways were significantly represented by differentially-expressed genes at 30
min (Fig. 17). However, 30 and 114 signal transduction pathways were
significantly represented by differentially-expressed genes at 60 min and 180
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Figure 17. Signal transduction pathways represented by
differentially-expressed genes. Pathways or processes were
identified using Ingenuity Pathway Analysis as described in Materials
and Methods. The p-value is the measure of the likelihood that the
association of differentially expressed genes with a given pathway is
due to random chance.
min, respectively (not shown). In general, proinflammatory pathways such as
CD40 and epidermal growth factor (EGF) signaling are significantly represented
early following the PVL-PMN interaction (30 min). By comparison, cell fate
82

pathways such as death receptor signaling and myc-mediated apoptosis
signaling are more highly represented in PMNs by 60 and 180 min after exposure
to PVL (Fig. 17).

3.4.4 Expression of PMN genes encoding major transcription regulators is
increased following exposure to PVL.
Genes encoding proteins known to mediate the inflammatory response,
such as STAT3, SOCS3, JUNB, FOS, JUN, FOSB, FOSL1, and TANK were
upregulated 30 or 60 min after PMN exposure to 1 nM PVL (Fig. 18). Expression
of SOCS3 is regulated by the transcription factor STAT3. Therefore, upregulation
of SOCS3 is consistent with activation of STAT3 (39,40). JUNB, FOS, JUN,
FOSB, and FOSL1 encode proteins that dimerize and form the AP-1 transcription
factor, which is known to associate with NF-kappaB as a result of signal
transduction through proinflammatory pathways (41). TANK is a downstream
kinase involved in proinflammatory signal pathways that regulate NF-kappaB
activation (42,43). Genes involved in NF-kappaB signal transduction were
differentially expressed 180 min after exposure of PMNs to PVL. For example,
the gene encoding NF-kappaB inhibitor delta (IkBδ or NFKBID) was upregulated
and MAP3K3 (MEKK3) was downregulated, a finding consistent with a decrease
in IKKβ activation. Increased expression of MALT1, BCL10, and BCL3 by PMNs
after exposure to PVL suggests NF-kappaB is activated via nonclassical
pathways (42-46).
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Figure 18. PVL alters expression of genes encoding proteins
involved in inflammation and cell fate. Transcript levels were measured
as described in Materials and Methods. Colors represent the mean
increase or decrease (fold-change) in gene expression in PMNs treated
with native PVL relative to those treated with heat-denatured PVL (iPVL).
Results are the mean of three separate experiments or donors.
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3.4.5 Priming of PMNs with PVL alters expression of transcripts encoding surface
receptors and proinflammatory molecules.
Several PMN proinflammatory mediators were upregulated 180 min after
exposure to PVL (e.g., FCAR, encoding CD89; and CR1, which encodes CD35).
CD89 is an IgA receptor expressed on phagocytic cells and can promote
phagocytosis (47). CD35 binds the serum complement components C3b and
C4b at the microbial surface (48,49), thereby facilitating phagocytosis and
neutrophil activation through complement receptor activation (50).

Genes

encoding chemokines GROα (CXCL1), GROβ (CXCL2), and the cytokine
oncostatin M (OSM) were upregulated after exposure to PVL. GRO proteins
(members of the interleukin-8 superfamily) are expressed and secreted by
several cell types including neutrophils (51-54). Oncostatin M, a member of the
interleukin-6 family, is stored by mature PMNs as an active protein and released
following priming or activation. However, de novo synthesis of OSM is known to
occur under certain conditions (55) and previous studies have shown transient
upregulation of the transcript after phagocytosis (56,57).
Upregulation of PMN proinflammatory surface receptors and molecules
after PMN exposure to PVL (described above) is comparable to the increased
expression of proinflammatory molecules following priming with LPS and GMCSF (34,58-63). In contrast to other agonists, exposure of neutrophils to PVL
also culminated in relatively early downregulation of genes encoding other
surface receptors and cytokines involved in the inflammatory response (Fig. 18).
For example, IL5RA, IL1R1, IL1A, CCL23 (MIP-3), TNFRSF12A, TNFRSF10A,
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and TNF (encoding tumor necrosis factor alpha, TNFα) were repressed 60 min
after exposure of human neutrophils to PVL. Control of the TNFα-mediated
immune response is important for the resolution of inflammation (64-66).
Downregulation of transcripts encoding TNF receptors and TNFα at later time
points (60 and 180 min) provides support to the idea that there is eventual
moderation of the proinflammatory response induced by PVL, a phenomenon
consistent with induction of PMN apoptosis (Fig. 12A and B).
Expression of DIABLO (SMAC), CYCS, and APAF1 was increased after
incubation with PVL, findings compatible with activation of caspase 9. This
observation is consistent with previous findings reporting activation (proteolytic
cleavage) of caspase 9 and caspase 3 following exposure of PMNs to
recombinant PVL (26). Furthermore, expression of the anti-apoptotic genes XIAP
and CFLAR (c-FLIP) was repressed (67,68). Taken together, these data suggest
that exposure of human PMNs to PVL activated proinflammatory signal
transduction pathways, an event followed by differential expression of genes
involved in cell fate.

3.4.6 Multiple proinflammatory molecules are released from neutrophils following
PVL priming.
Inasmuch as PVL primes neutrophils for enhanced function and caused
upregulation of transcripts involved in the proinflammatory response, we next
measured release of proinflammatory molecules from PMNs following exposure
to sublytic concentrations of PVL (Table 1). PVL caused release of multiple
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Table 1. PVL-mediated release of proinflammatory molecules. Supernatants
were analyzed by RBM using microsphere-based immuno-multiplexing. Asterisks
indicate molecules whose concentrations remained below or at the lower limit of
detection (LOD) and the LODs were used to calculate a conservative p value.

Control (ng/mL)

+1 nM PVL (ng/mL)

(mean ± S.D.)

(mean ± S.D.)

(n = 4)

(n = 4)

Ferritin

0.5200 ± 0.1226

19.50 ± 2.887

0.0009

Vascular endothelial growth factor

0.0198 ± 0.0128

0.5740 ± 0.1740

0.007

Interleukin-1 receptor antagonist

*0.0067 ± 0.0025

0.0408 ± 0.0091

0.009

Tumor necrosis factor receptor 2

0.1860 ± 0.1132

0.4380 ± 0.1282

0.01

Insulin-like growth factor-1

6.630 ± 0.9500

10.40 ± 1.451

0.01

Prostatic acid phosphatase

0.0500 ± 0.0083

0.4200 ± 0.1547

0.02

Myeloperoxidase

342.3 ± 98.10

9003 ± 3642

0.02

Growth hormone

*0.0200 ± 0.000

0.0500 ± 0.0163

0.02

Serum amyloid P component

2.500 ± 2.400

4.000 ± 2.200

0.02

CD40

*0.0044 ± 0.000

0.0120 ± 0.0034

0.03

Plasminogen activator inhibitor 1

0.0500 ± 0.0123

0.0800 ± 0.0149

0.03

EN-RAGE

16.75 ± 10.31

143.8 ± 68.04

0.04

Interleukin-8

0.0061 ± 0.0028

0.0334 ± 0.0166

0.05

Cancer antigen 19-9 (µU/mL)

*320.0 ± 0.000

845.0 ± 349.9

0.06

Tissue inhibitor of metalloproteinases 1

0.2700 ± 0.1857

1.083 ± 0.7054

0.06

Carcinoembryonic antigen

*0.0400 ± 0.0040

0.1700 ± 0.0851

0.06

Factor VII

*0.1100 ± 0.000

0.4000 ± 0.2335

0.09

Adipoliporotein (a)

23.00 ± 8.100

39.00 ± 14.50

0.1

Interleukin-6

*0.0004 ± 0.000

0.0011 ± 0.0007

0.1

Tyroid stimulating hormone (µIU/mL)

*0.0041 ± 0.000

0.0080 ± 0.0041

0.2

Interleukin-1 beta

*0.0002 ± 0.000

0.0048 ± 0.0062

0.2

Protein
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P value

proinflammatory mediators, including IL-8, IL-6, VEGF, and myeloperoxidase
(MPO),

from

human

neutrophils.

In

addition,

we

observed

significant

accumulation of tumor necrosis factor receptor 2 (TNFR2) and IL-1 receptor
antagonist (IL-1RA) in RPMI 1640 culture media after incubation of PMNs with
PVL. Neutrophils are known to shed TNFR2 following stimulation with fMLP and
GM-CSF, thereby decreasing the subsequent PMN response to TNFα (64).
PMNs stimulated in vitro with LPS or GM-CSF released of IL-1β and IL-1RA;
however, concentrations of IL-1RA are significantly higher than those of IL-1β
(66). Consistent with these previous studies, 1 nM PVL caused accumulation of
10 times more IL-1RA than IL-1β in PMN culture media (there was 0.0408 ±
0.0091 ng/ml IL-1RA and 0.0048 ± 0.0062 ng/ml IL-1β in culture media after
exposure to PVL).

3.5 Discussion
Recent multinational phase III clinical trials indicate that presence of pvl
genes is not the primary determinant of outcome in patients with MRSA skin and
soft tissue infection. In fact, individuals with PVL-positive infections were more
likely to be cured (69,70). It is also noteworthy that the concentration of PVL
achieved during S. aureus infection in vivo may be insufficient to cause PMN
lysis (71,72), findings that bring into question the role of PVL as a cytolytic toxin.
Antibodies against PVL are present in individuals with previous confirmed S.
aureus infections caused by either PVL-positive or PVL-negative strains (73,74).
These observations suggest that some of the antibodies were originally elicited
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by two-component toxins other than PVL, but the antibodies cross-react with
PVL. Recurrent infections with PVL-positive S. aureus strains occur in patients
that have anti-PVL antibodies, findings that suggest PVL has little or no role in
establishment of infection (75). Furthermore, a previous study demonstrated that
administration of anti-PVL antibodies prior to USA300 or USA400 infection (pvlpositive) hindered clearance of infection (76). This observation seems at variance
with the presumed role of during infection (i.e., cytolytic toxin that enhances
virulence), but is consistent with the ability of the molecule to function as a
neutrophil priming agent.
The cytolytic properties of PVL are well known from extensive work in
vitro. However, there is paucity of evidence to indicate that the primary function
of PVL in vivo is cytolysis of host leukocytes. Furthermore, in vitro studies
indicate S. aureus is rapidly ingested by neutrophils and that these host
phagocytes undergo rapid lysis independent of PVL (7,29). Thus, the role played
by PVL during infection remains unclear.
Sublytic concentrations of PVL are known to prime neutrophils for
enhanced release of O2-, and cause release of IL-8, IL-6 and PMN granule
contents, such as MPO and lysozyme (18-21). Previous studies demonstrated
that granule exocytosis occurs in intact PMNs following incubation with PVL (77).
Furthermore, Konig et al. reported that inhibition of protein tyrosine kinases
decreases release of IL-8 from PMNs exposed to sublytic levels of PVL (20).
Consistent with these previous studies, we found that neutrophils incubated with
1 nM PVL remained intact, as there was little or no release of LDH using these
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assay conditions (Fig. 11C). Taken together, these data provide strong support
to the idea that PVL-mediated release of neutrophil proinflammatory molecules
was caused by activation of signal transduction pathways rather than cytolysis.
In accordance with previous work, PVL had proinflammatory effects on
human neutrophils, including priming for enhanced release of O2-, upregulation of
CD11b, and secretion of TNFR2, IL-1RA, and IL-1β. The proinflammatory
response elicited by PVL is similar to that caused by inflammatory cytokines or
bacterial components such as GM-CSF and LPS (34,62,78). One major
difference is that exposure of PMNs to PVL caused release of MPO, a protein
sequestered in azurophilic granules (15) (Table 1). Exocytosis of azurophilic
granules is not typical of priming with GM-CSF (79), IL-8 (80), or LPS (81).
Rather, this phenomenon typically indicates full activation of neutrophils. PVL
also accelerated PMN apoptosis at a concentration that elicits a proinflammatory
response (Fig. 12A and B), which is at variance with the ability of other priming
agents to extend PMN survival in vitro. Our finding that genes encoding
apoptosome proteins, DIABLO (SMAC), CYCS, and APAF1, were upregulated
after exposure to PVL suggests that the caspase 9/3 pathway participates in
PVL-mediated apoptosis (Fig. 18). Previous studies have linked induction of
PMN apoptosis to inactivation of the NF-kappaB pathway (82,83). Differential
expression of PMN genes directly transcribed by NF-kappaB subunits (ICAM1,
TNF) and those encoding proteins that in regulate NF-kappaB activity (BCL3,
BCL10, and MALT1) suggest this pathway is activated following exposure to
PVL.
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PMNs are exposed to a multitude of proinflammatory molecules during
infection in vivo and different combinations of stimuli are known to elicit different
PMN responses (84). The application of this idea to PVL-positive S. aureus
infections is perhaps reflected by our finding that fMLP, GM-CSF, and IL-8 alter
the ability of PVL to interact with PMNs (Fig. 14A and B). Data in this study
suggest that sublytic concentrations of PVL prime PMNs for enhanced
microbicidal capacity. This notion is supported by Yoong et al. (76), in which antiPVL rabbit sera inhibited PMN killing of several PVL-positive S. aureus strains in
vitro. By comparison, killing of isogenic pvl mutants by PMNs was similar in the
presence or absence of anti-PVL antibody (76). Collectively, these observations
suggest that PVL can enhance rather than hinder the host innate immune
response to S. aureus infection. Nonetheless, the ability of PVL to alter PMN
bactericidal activity in vivo merits further investigation. Elucidation of activated
secondary messenger proteins following such stimulation with PVL may provide
new insight into the ability of specific agonists to elicit differential responses from
human neutrophils.
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CHAPTER FOUR
SUMMARY

4.1 Significance of the work presented in this dissertation

4.1.1 S. aureus virulence and cytolytic toxins.
The success of S. aureus as a human and animal pathogen is largely
associated with its ability to produce a multitude of toxins. For example, S.
aureus produces several cytolytic molecules with well-characterized in vitro
activity that contribute to virulence. The host range is varied among S. aureus
toxins and some, such as the alpha-type phenol soluble modulins (PSMs), have
the ability to target a broad range of host cells. PSMs are a group of relatively
short amphipathic peptides that are encoded in the S. aureus core genome (1).
Importantly, PSMs are one of the few molecules known to contribute to the
enhanced virulence phenotype of CA-MRSA strains such as USA300 (1). Alphahemolysin (α-hemolysin, Hla) is an exotoxin that is encoded in the core genome
of virtually all S. aureus strains. Hla is secreted as a soluble monomer, forms a
heptameric pore in the plasma membrane of target cells (2), and has cytolytic
activity toward epithelial cells, erythrocytes, monocytes, lymphocytes, fibroblasts,
and platelets (3,4). In addition, S. aureus produces several bicomponent poreforming toxins (PFTs) that are tropic for leukocytes such as macrophages,
monocytes, and neutrophils. The pore-forming activity of this group of related
leukotoxins requires two components, a LukS subunit and a LukF subunit.
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Alternating LukF and LukS components form a pore in the plasma membrane of
leukocytes. PFTs that are expressed by S. aureus include gamma-hemolysin (γhemolysin, Hlg), LukG-LukH (LukGH), LukD-LukE (LukDE), and PVL (comprised
of LukS-PV and LukF-PV) (4-6). Similar to the hla operon, genes that encode Hlg
(hlgABC) and LukGH (lukG/H) are essentially ubiquitous in clinical isolates of S.
aureus (6,7). Two combinations of Hlg subunits, HlgA-HlgB or HlgA-HlgC,
aggregate on the surface of erythrocytes and leukocytes and cause lysis of these
cells (8-10). LukGH is freely secreted and bound to the surface of S. aureus. This
toxin was recently shown to cause lysis of neutrophils (6). LukDE is encoded in
the genome of ~30% of clinical isolates (11); however, the lukDE operon is
harbored by many prominent HA-MRSA and CA-MRSA strains (11-13). This
bicomponent PFT is weakly leukotoxic (11). PVL lyses neutrophils and other
myeloid cells in vitro and many CA-MRSA strains harbor genes that encode PVL
(lukS/F-PV) (12,14,15). However, only 2-5% of all clinical S. aureus isolates
contain lukS/F-PV (7,16,17).
There is striking redundancy in cytolytic activity among the S. aureus
leukotoxins. Presumably, destruction of neutrophils and other leukocytes confers
an increased ability of S. aureus to evade the host innate immune response. It
remains a mystery why S. aureus in general produce so many molecules that
potentially have a similar role in virulence. S. aureus causes a wide range of
infections with varied degrees of severity (16,18-20). Perhaps such redundancy
in toxin function is advantageous for the pathogen, as it might enable S. aureus
to colonize and/or cause infection in several niches in the human host. For
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example, it is known that expression of PVL and Hlg by S. aureus is highly
influenced by in vitro culture conditions (21,22). These findings underscore the
notion that specific conditions in vivo likely impact expression of cytolytic toxins
and could thereby influence the outcome of infection. In addition, the combination
of PVL and LukGH causes lysis of human neutrophils that is greater than that
caused by either toxin alone, suggesting that specific leukotoxin combinations
are additive or synergistic (6). The concerted action of both toxins may further
enhance the success of S. aureus as a human pathogen.
PVL-positive strains compromise a small fraction of all S. aureus clinical
isolates, and correspondingly, there is an association of these strains with a
relatively small subset of skin infections (e.g. furuncles and carbuncles) and
necrotizing pneumonia with antecedent influenza (14,19,23-25). It is therefore
possible that PVL confers some advantage to S. aureus under specific conditions
or niches in vivo. The acquisition of lukS/F-PV requires horizontal transfer of a
prophage (26,27). Therefore, acquisition of lukS/F-PV is either uniquely not
important (with the possible exception of particular S. aureus infections) and/or
the genetic background of specific S. aureus lineages may be less compatible
with prophage insertion into the genome (restriction system), thus limiting the
number of PVL-positive strains. Inasmuch as the vast majority of S. aureus
clinical isolates encode Hla, PSMs, and other molecules that contribute to
infection, PVL is clearly not required to cause disease. Additionally, epidemic
PVL-positive CA-MRSA lineages remain fairly specific in geographic distribution
(28), which suggests that factors other than PVL determine global segregation of
108

pathogenic strains. S. aureus, including PVL-positive strains, presumably have
had the opportunity to disseminate to any global region, given the high levels of
international travel. The limited prominence of PVL-positive clinical isolates
overall supports the notion that PVL may have a role in specific types of infection
or function only in the presence of particular host factors.
4.1.2 Does PVL contribute to the lysis of human neutrophils?
Historic studies clearly demonstrated that purified native PVL is cytolytic
toward rabbit and human neutrophils (29-31). In addition, PVL-mediated cytolysis
is concentration-dependent and concentrations of PVL less than 2 nM cause
formation of membrane pores but little or no cytolysis (21,30,31). Genestier et al.
(32) demonstrated that cytolysis of human neutrophils occurs following incubaton
with 200 nM of recombinant PVL (rPVL). In contrast, exposure of PMNs to a
sublytic level of rPVL (5 nM) accelerates neutrophil apoptosis rather than causing
necrosis (lysis). Similarly, a study by Loffler et al. (17) confirmed the finding that a
low concentration of rPVL (80 ng/ml or ~1.1 nM) accelerates neutrophil
apoptosis. However, these authors also reported that 80 ng/ml causes a 90%
decrease in intact cells (reported as % of intact cells) at 20 min, a finding
consistent with a high degree of PMN lysis under those assay conditions. The
apparent discrepancy in these reports is likely explained by differences in
methodology used to determine cell lysis. For example, Genestier et al. (32)
measured cell lysis by microscopy, whereas Loffler et al. (17) used a less direct
method (uptake of propidium iodide) that determines pore formation and not
necessarily cell lysis. There was a similar discrepancy between Loffler et al. (17)
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and Voyich et al. (33). These studies examined the contribution of PVL to PMN
lysis in vitro by use of S. aureus culture supernatants. Voyich et al. (33) found
that culture supernatants derived from USA300 and USA400 wild type (WT) or
isogenic lukS/F-PV deletion (Δpvl) strains caused comparable levels of PMN lysis
(33). By contrast, Loffler et al. (17) reported that culture supernatants from
USA300Δpvl caused decreased neutrophil lysis compared to those from the
corresponding WT strain. By inspection, the disparities between these data
appear to be the result of two factors: 1) utilization of different methods to assess
PMN lysis, and 2) use of culture supernatants from different in vitro growth
media. Loffler et al. (17) determined levels of cytolysis by measuring uptake of
propidium iodide (PI) while Voyich et al. (33) measured extracellular release of
lactate dehydrogenase (LDH). Although uptake of PI was used as an indicator of
neutrophil lysis, such an approach operates under the assumption that PVLmediated pore formation correlates directly with cytolysis. However, results
presented in Chapter 2 of this dissertation demonstrate that there is not a direct
correlation between EtBr uptake (pore formation) and LDH release by human
PMNs. Therefore, Loffler et al. (17) measured cell membrane permeability but
not necessarily necrosis.
Some of the incongruity in these studies in vitro is also likely attributed to the
use of supernatants from different culture media. This idea is supported by
results presented in Chapter 2 indicating that production of PVL is highly
influenced by different culture conditions in vitro. Growth of PVL-positive strains
in CCY, particularly USA300, is optimal for high production of PVL, whereas
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growth in TSB or 100% human serum is not. Accordingly, the variability in
quantities of PVL present in culture supernatants from different media in vitro
partly explains why there are disparities in the literature as exemplified by Voyich
et al. (33) and Loffler et al. (17). Taken together, these data indicate that
differential expression of PVL in vitro alters the contribution of PVL to pore
formation and cytolytic activity of culture supernatants (Chapter 2). PVL-positive
culture supernatants from S. aureus growth media that more closely represent in
vivo growth conditions (e.g., human serum) support little or no accumulation of
PVL. Furthermore, culture supernatants that have limited PVL-mediated cytolytic
activity (Chapter 2, Fig. 8 TSB) contain quantities of PVL comparable to that in
material recovered from human S. aureus infections (34,35). These findings
indicate that in vitro assays with culture supernatants are of limited utility for
estimating the contribution of PVL to S. aureus virulence. Consistent with this
idea, there is no correlation between levels of PVL produced in vitro by clinical
isolates and disease severity (36). The observation that concentrations of PVL in
vivo (34,35) are largely limited to those that cause pore formation but limited lysis
in vitro (Chapter 2) challenges the widely accepted notion that the primary role of
PVL during infection is to cause cytolysis of leukocytes.

4.1.3 PVL as an immune modulatory agent.
Given that in vivo expression of PVL likely does not achieve a
concentration necessary to cause significant neutrophil lysis, we examined the
ability of sublytic concentrations of PVL to alter PMN function (Chapter 3).
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Sublytic concentrations of PVL prime neutrophils for enhanced release of O2-,
and induce extracellular release of IL-8, IL-6 and PMN granule contents (37-40).
Previous studies indicate that there is optimal release of O2- from PVL-primed
neutrophils following stimulation with fMLP (41,42, and confirmed in Chapter 3).
However, the molecular basis for PVL-mediated priming of neutrophils is
unknown.
Our results indicate that PVL elicits a proinflammatory response from
human PMNs. One of the major goals of this dissertation (Chapter 3) was to
characterize the molecular mechanism by which PVL primes neutrophils for
enhanced response to a secondary agonist. Enhanced release of ROS from
PMNs primed with PVL requires a specific order of events as indicated by O2release assays (Fig. 13A and 15). Neutrophils primed with IL-8 or GM-CSF have
increased susceptibility to PVL-mediated pore formation, whereas cells primed
with fMLP or activated with PMA are resistant to pore formation (Fig. 14). These
data suggest that the activation state of the human neutrophil determines the
extent to which PVL is capable of causing pore formation and O2- release.
Inasmuch as neutrophils interact with proinflammatory molecules such as IL-8
during S. aureus infection, alterations in microbicidal activity under these
conditions merits investigation. To further examine the molecular basis of PVLmediated priming, PMNs were exposed to PVL and the culture medium was
analyzed for accumulation of molecules known to be involved in the
proinflammatory response. We discovered that several notable proinflammatory
agents were released by PMNs following exposure to PVL (Table 1), including
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molecules previously reported to be released by PMNs under these conditions
(37-40). Collectively, these data provide new insight into how PVL in vivo might
alter the outcome of infection.
Microarray experiments with PVL-treated PMNs were performed to gain a
broad understanding of the molecular mechanism of PVL-mediated neutrophil
priming. The microarray data suggest that PMN exposure to PVL triggers
activation of STAT3 and NF-kB signal transduction pathways. Both of these
pathways are known to mediate the proinflammatory response in multiple cell
types, including neutrophils. These data provide a basis for future studies to
explore how PVL, as an immune modulatory agent, alters the host-S.aureus
interaction.
Although our work reveals the potential of PVL as an immune-modulatory
agent, such a function remains to be determined in vivo. Nonetheless, recent
studies have shown that Hla, another S. aureus cytolytic toxin, has an immune
modulatory function in vivo. Hla is essential for mortality in mouse models of
pneumonia and the level of Hla expression correlates with severity of infection
(43). Production of Hla during experimental S. aureus pneumonia in mice
increases quantities of CXCL1, CXCL2, and TNFα present in lung tissue, which
in turn recruits neutrophils to the lungs (44). This enhanced neutrophil
recruitment ultimately results in severe lung tissue destruction and death. It is
well accepted that neutrophils can cause significant host tissue damage under
conditions in which the inflammatory response is dysregulated and/or there is not
timely removal of effete cells (45,46). Hla in vitro elicits release of
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proinflammatory molecules such as IL-8, IL-1β and TNFα from monocytes and
endothelial cells (47-49). These findings indicate that the role of S. aureus
exotoxins in pathogenesis is not be solely based on cytolytic activity. Rather, the
host inflammatory response elicited by secreted exotoxins is likely a major factor
in determining the outcome of S. aureus infection. This notion is supported
further by Bubeck Wardenburg et al. (50) who reported that protection against
CA-MRSA pneumonia is associated with different cytokine profiles compared to
unvaccinated controls.
In contrast to Hla, there is little in vivo evidence to suggest that PVL
increases the severity of experimental CA-MRSA pneumonia (43,51), with the
exception of a single study (52). Diep et al. (52) reported a moderate increase in
mortality and lung inflammation following infection with a high bacterial inoculum.
S. aureus necrotizing pneumonia is typically associated with S. aureus strains
that contain genes encoding for PVL (14,23,25), and Diep et al. (52)
demonstrated that purified PVL causes lung inflammation. A caveat of these
findings is that a large quantity of PVL (12 µg) is needed to cause accumulation
of IL-8 and MCP-1 in rabbit lungs (52). Diep et al. (52) proposed that increased
severity of S. aureus infection is attributed in part to degranulation of PMNs
following exposure to PVL in vivo, which in turn causes damage to the lungs and
prolongs the proinflammatory response. It is notable that Diep et al. (52) utilized
a very large inoculum of PVL-positive S. aureus in the pneumonia model and a
high concentration of purified PVL to elicit a proinflammatory response in the
rabbit lung.
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Hla clearly contributes to the severity of staphylococcal disease in animal
models, while the contribution of PVL is limited or undetectable. Perhaps this
difference can be partially explained by the ability of Hla to target a much wider
range of cell types as compared to PVL. As demonstrated by Suttorp et al. (53),
exposure of pulmonary endothelial monolayers to Hla increases permeability of
the monolayer by stimulating cell retraction, i.e. formation of paracellular gaps.
These results suggest that Hla disrupts the air-blood barrier in pulmonary tissue
not by cytolysis but by altering cell morphology and/or function. Subsequent
studies by McElroy et al. (54) and Bubeck Wardenburg et al. (50) demonstrated
that expression of Hla in an animal pneumonia model caused disruption of the
air-blood barrier via destruction of lung tissue.
In comparison to Hla, PVL may have a more subtle role in the progression
of staphylococcal pneumonia and/or may contribute in rare syndromes (i.e.,
necrotizing pneumonia). It is also possible that particular host factors increase
leukocyte susceptibility to PVL or cause an aberrant proinflammatory response
following exposure to PVL. Further studies will be necessary to test these
hypotheses.
There is redundancy in the cytolytic and proinflammatory function of S.
aureus cytolytic toxins; however, studies in vivo demonstrate that not all are
created equal. Hla is a key virulence factor in staphylococcal pneumonia and
SSTIs as exemplified by the ability of anti-Hla antibodies to protect S. aureusinfected mice from severe or lethal disease (50,55). By comparison, anti-PVL
antibodies confer no protection against S. aureus infection in animal pneumonia
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models (50). Antibodies that cross-react with PVL are present in the general
human population, with or without a medical history of S. aureus infection (5659). Notably, anti-PVL antibodies fail to protect individuals from recurrent
infections caused by PVL-positive CA-MRSA strains USA300 and USA400
(60,61).

4.1.4 Concluding thoughts.
The ability of sublytic concentrations of PVL to augment the
proinflammatory response (Chapter 3 and 37-40) could be detrimental to
surrounding host tissues. Increased release of proinflammatory agents, such as
IL-8 and IL-1β, from leukocytes would lead to increased inflammation and the
potential for unintended host tissue damage. A countering argument to this
notion is that the PVL-mediated release of inflammatory molecules enhances the
innate immune response, and therefore, expression of PVL in vivo could be
advantageous to the host for clearance of infection. This idea is further supported
by Yoong et al., who demonstrated reduced clearance of USA300 and USA400
infection after administration of anti-PVL antibodies (62). In light of these and
other previous findings that indicate anti-PVL antibodies are not protective
against subsequent S. aureus infection (60,61), it is particularly concerning that a
monovalent or bivalent recombinant LukS-PV toxoid vaccine human trial is
underway (http://www.clinicaltrials.gov/ct2/show/NCT01011335?term=panton
valentine+leukocidin&rank=2). Host production of anti-PVL antibodies after
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vaccination with this LukS-PV toxoid may actually worsen the outcome of S.
aureus infection rather than providing some benefit to the host.
Based on previous studies and work presented in this dissertation, we
propose that PVL functions primarily as an immune modulatory agent rather than
a cytolytic toxin. How would a PVL-enhanced proinflammatory response be
advantageous to S. aureus as a commensal organism or pathogen? It is possible
that such a proinflammatory response limits dissemination and disease severity,
thereby promoting a long-term commensal interaction with the human host. PVLmediated alterations in the proinflammatory response are perhaps advantageous
for S. aureus, particularly in certain host niches or time points during infection.
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